BBSI Reports Fourth Quarter and Full Year 2020 Financial Results

– Q4 2020 Net Income of $7.2 Million, or $0.93 per Diluted Share –

– Full Year 2020 Net Income of $33.8 Million, or $4.39 per Diluted Share –

VANCOUVER, Wash., March 03, 2021 (GLOBE NEWSWIRE) — Barrett Business Services, Inc. (“BBSI” or the “Company”) (NASDAQ: BBSI), a leading provider of business management solutions, reported financial results for the fourth quarter and full year ended December 31, 2020.

Fourth Quarter 2020 Financial Summary vs. Year-Ago Quarter

  • Net revenues down 5% to $233.2 million.
  • Gross billings up 1% to $1.60 billion.
  • Average worksite employees (“WSEs”) down 6%.
  • Net income of $7.2 million, or $0.93 per diluted share, compared to $11.7 million, or $1.51 per diluted share.
  • Unrestricted cash and investments up 34% to $169.9 million.

Full Year 2020 Financial Summary vs. 2019

  • Net revenues down 7% to $880.8 million.
  • Gross billings down 1% to $5.92 billion.
  • Average WSEs down 5%.
  • Net income of $33.8 million, or $4.39 per diluted share, compared to $48.3 million, or $6.27 per diluted share.

“Once again, we had a stronger-than-expected quarter, finishing out an extremely challenging year with continued resilience,” said BBSI President and CEO, Gary Kramer. “While business volume and earnings were impacted by the pandemic, I am extremely proud of the work that our teams performed throughout the year. We helped thousands of small businesses in a year of great need while at the same time implementing strategies to make BBSI even stronger coming out of the COVID-19 pandemic.”

Fourth Quarter 2020 Financial Results

Net revenues in the fourth quarter of 2020 decreased 5% to $233.2 million compared to $245.2 million in the fourth quarter of 2019.

Total gross billings in the fourth quarter increased 1% to $1.60 billion compared to $1.59 billion in the same year-ago quarter (see “Key Performance Metrics and Non-GAAP Financial Measures” below). The increase was primarily due to higher average payroll per WSE, partially offset by a 6% decrease in average WSEs attributable to the effects of the ongoing COVID-19 pandemic.

Non-GAAP gross workers’ compensation expense as a percent of gross billings was 3.7% in the fourth quarter of 2020 and benefited from a favorable one-time adjustment of prior accident year liability of $1.2 million, as well as other cost-saving measures. This compares to 4.2% in the fourth quarter of 2019.

Net income for the fourth quarter of 2020 decreased to $7.2 million, or $0.93 per diluted share, compared to $11.7 million, or $1.51 per diluted share, in the year-ago quarter. The decline in net income is primarily attributable to a lower level of favorable development on prior year claims and lower investment income in the quarter.

Full Year 2020 Financial Results

Net revenues in 2020 decreased to $880.8 million compared to $942.3 million in 2019.

Total gross billings in 2020 decreased 1% to $5.92 billion compared to $5.97 billion in 2019 (see “Key Performance Metrics and Non-GAAP Financial Measures” below). The decrease was directly attributable to the effects of the ongoing COVID-19 pandemic and its impact on the economy and operations of small businesses, including a decrease in average WSEs of 5% for the year, offset in part by higher average payroll per WSE.

Non-GAAP gross workers’ compensation expense as a percent of gross billings was 3.8% in 2020 and benefited from favorable adjustments of prior accident year liability of $6.4 million, as well as other cost-saving measures. This compares to 4.1% in 2019.

Net income in 2020 decreased to $33.8 million, or $4.39 per diluted share, compared to $48.3 million, or $6.27 per diluted share, in 2019. The decline in net income is primarily attributable to a lower level of favorable development on prior year claims compared to 2019, as well as lower billing volume and investment income, partially offset by reductions in operating expenses in 2020.

Liquidity

As of December 31, 2020, unrestricted cash and investments increased 34% to $169.9 million compared to $127.2 million in the year-ago quarter. BBSI remains debt free apart from the $3.7 million mortgage on its corporate headquarters.

Capital Allocation

BBSI’s board of directors has confirmed its regular quarterly cash dividend of $0.30 per share. The cash dividend will be paid on April 2, 2021 to all stockholders of record as of March 19, 2021. Since the repurchases reported in its last earnings release, the Company also repurchased an additional 28,000 shares at an average price of $71.80 per share.

Outlook

In 2021, BBSI expects the following:

  • Gross billings growth of 2% to 5%
  • Growth in the average number of WSEs of 1% to 3%
  • Gross margin as a percent of gross billings of 2.9% to 3.1%
  • Effective annual tax rate of 21% to 23%

Conference Call

BBSI will conduct a conference call on Wednesday, March 3, 2021, at 5:00 p.m. Eastern time (2:00 p.m. Pacific time) to discuss its financial results for the fourth quarter and the full year ended December 31, 2020.

BBSI’s CEO Gary Kramer and CFO Anthony Harris will host the conference call, followed by a question and answer period.

Date: Wednesday, March 3, 2021
Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific time)
Toll-free dial-in number: 1-877-407-4018
International dial-in number: 1-201-689-8471
Conference ID: 13716825

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Gateway Investor Relations at 1-949-574-3860.

The conference call will be broadcast live and available for replay here and via the Investors section of the BBSI website at www.bbsi.com.

A replay of the conference call will be available after 8:00 p.m. Eastern time on the same day through April 3, 2021.

Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 13716825

Key Performance Metrics and Non-GAAP Financial Measures        

We report PEO revenues net of direct payroll costs because we are not the primary obligor for wage payments to our clients’ employees. However, management believes that gross billings and wages are useful in understanding the volume of our business activity and serve as an important performance metric in managing our operations, including the preparation of internal operating forecasts and establishing executive compensation performance goals. We therefore present for purposes of analysis gross billings and wage information for the three and twelve months ended December 31, 2020 and 2019.

  (Unaudited)   (Unaudited)
  Three Months Ended December 31,   Year Ended December 31,
(in thousands) 2020   2019   2020   2019
Gross billings $ 1,603,521   $ 1,593,919   $ 5,924,539   $ 5,971,008
PEO and staffing wages $ 1,387,816   $ 1,365,527   $ 5,098,604   $ 5,090,943

Because safety incentives represent consideration payable to PEO customers, safety incentive costs are netted against PEO revenue in our consolidated statements of operations. Management considers safety incentives to be closely connected to our workers’ compensation program because they encourage client companies to maintain safe work practices and minimize workplace injuries. We therefore present below for purposes of analysis non-GAAP gross workers’ compensation expense, which represents workers’ compensation costs including safety incentive costs. We believe this non-GAAP measure is useful in evaluating the total costs of our workers’ compensation program.

  (Unaudited)   (Unaudited)
  Three Months Ended December 31,   Year Ended December 31,
(in thousands) 2020   2019   2020   2019
Workers’ compensation $ 54,624   $ 57,600   $ 200,744   $ 211,890
Safety incentive costs   4,394     8,862     23,544     31,663
Non-GAAP gross workers’ compensation $ 59,018   $ 66,462   $ 224,288   $ 243,553

In monitoring and evaluating the performance of our operations, management also reviews the following ratios, which represent selected amounts as a percentage of gross billings. Management believes these ratios are useful in understanding the efficiency and profitability of our service offerings.

  (Unaudited)   (Unaudited)
  Percentage of Gross Billings   Percentage of Gross Billings
  Three Months Ended December 31,   Year Ended December 31,
  2020   2019   2020   2019
PEO and staffing wages 86.5%   85.7%   86.1%   85.3%
Payroll taxes and benefits 6.6%   6.8%   7.1%   7.2%
Non-GAAP gross workers’ compensation 3.7%   4.2%   3.8%   4.1%
Gross margin 3.2%   3.4%   3.1%   3.5%

We refer to employees of our PEO clients as WSEs. Management reviews average and ending WSE growth to monitor and evaluate the performance of our operations. Average WSEs are calculated by dividing the number of unique individuals paid in each month by the number of months in the period. Ending WSEs represents the number of unique individuals paid in the last month of the period.

  (Unaudited)
  Year Ended December 31,
  2020   % Change   2019   % Change   2018
Average WSEs   108,249     -5.3 %   114,341     4.1 %   109,859
Ending WSEs   109,292     -4.6 %   114,584     4.6 %   109,527

About BBSI

BBSI (NASDAQ: BBSI) is a leading provider of business management solutions, combining human resource outsourcing and professional management consulting to create a unique operational platform that differentiates it from competitors. The Company’s integrated platform is built upon expertise in payroll processing, employee benefits, workers’ compensation coverage, risk management and workplace safety programs, and human resource administration. BBSI’s partnerships help businesses of all sizes improve the efficiency of their operations. The Company works with more than 7,500 clients across all lines of business in 39 states. For more information, please visit www.bbsi.com.

Forward-Looking Statements

Statements in this release about future events or performance, including expectations regarding the effects of the COVID-19 pandemic on our business operations and product relevance, and future growth in gross billings, average number of WSEs, earnings per share, workers’ compensation expense as a percentage of gross billings, gross margin as a percentage of gross billings and effective annual tax rates, are forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that may cause the actual results of the Company to be materially different from any future results expressed or implied by such forward-looking statements. Factors that could affect future results include economic conditions in the Company’s service areas, the effects of governmental orders imposing business closures and stay-at-home and physical distancing requirements, the effect of changes in the Company’s mix of services on gross margin, the Company’s ability to retain current clients and attract new clients and to achieve revenue growth, the availability of financing or other sources of capital, the Company’s relationship with its primary bank lender, the potential for material deviations from expected future workers’ compensation claims experience, changes in the workers’ compensation regulatory environment in the Company’s primary markets, litigation costs, security breaches or failures in the Company’s information technology systems, the collectability of accounts receivable, changes in executive management, the carrying value of deferred income tax assets and goodwill, and the effects of the pandemic, economic slowdown, and conditions in the global capital markets on the Company’s investment portfolio, among others. Other important factors that may affect the Company’s prospects are described in the Company’s 2019 Annual Report on Form 10-K and in subsequent reports filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934. Although forward-looking statements help to provide complete information about the Company, readers should keep in mind that forward-looking statements are less reliable than historical information. The Company undertakes no obligation to update or revise forward-looking statements in this release to reflect events or changes in circumstances that occur after the date of this release.


Barrett Business Services, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

  December 31,   December 31,
(in thousands) 2020   2019

Assets
         
Current assets:          
Cash and cash equivalents $ 68,688   $ 44,570
Investments   101,244     82,590
Trade accounts receivable, net   118,506     163,561
Income taxes receivable   6,485     1,335
Prepaid expenses and other   15,961     14,919
Restricted cash and investments   96,991     116,873
Total current assets   407,875     423,848
Property, equipment and software, net   34,916     31,724
Operating lease right-of-use assets   23,025     23,805
Restricted cash and investments   258,153     327,326
Goodwill   47,820     47,820
Other assets   3,161     3,618
Deferred income taxes       2,788
  $ 774,950   $ 860,929

Liabilities and Stockholders’ Equity
         
Current liabilities:          
Current portion of long-term debt $ 221   $ 221
Accounts payable   4,746     5,993
Accrued payroll, payroll taxes and related benefits   149,989     174,168
Current operating lease liabilities   7,539     6,671
Other accrued liabilities   7,275     8,846
Workers’ compensation claims liabilities   102,040     118,273
Safety incentives liability   18,827     27,950
Total current liabilities   290,637     342,122
Long-term workers’ compensation claims liabilities   255,706     320,713
Long-term debt   3,510     3,730
Deferred income taxes   4,518    
Long-term operating lease liabilities   16,419     17,883
Customer deposits and other long-term liabilities   5,925     4,682
Stockholders’ equity   198,235     171,799
  $ 774,950   $ 860,929


Barrett Business Services, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

(in thousands, except per share amounts) Three Months Ended   Year Ended
  December 31,   December 31,
  2020   2019   2020   2019
Revenues:                      
Professional employer service fees $ 204,268   $ 212,033   $ 777,430   $ 819,873
Staffing services   28,908     33,119     103,394     122,438
Total revenues   233,176     245,152     880,824     942,311
Cost of revenues:                      
Direct payroll costs   22,055     25,157     78,380     92,455
Payroll taxes and benefits   105,518     108,372     418,793     429,713
Workers’ compensation   54,624     57,600     200,744     211,890
Total cost of revenues   182,197     191,129     697,917     734,058
Gross margin   50,979     54,023     182,907     208,253
Selling, general and administrative expenses   40,959     40,362     141,916     153,879
Depreciation and amortization   1,332     977     4,844     3,886
Income from operations   8,688     12,684     36,147     50,488
Other income, net   756     2,704     6,449     10,650
Income before income taxes   9,444     15,388     42,596     61,138
Provision for income taxes   2,293     3,674     8,831     12,846
Net income $ 7,151   $ 11,714   $ 33,765   $ 48,292
Basic income per common share $ 0.94   $ 1.57   $ 4.46   $ 6.48
Weighted average basic common shares outstanding   7,590     7,505     7,577     7,451
Diluted income per common share $ 0.93   $ 1.51   $ 4.39   $ 6.27
Weighted average diluted common shares outstanding   7,686     7,736     7,688     7,699



Investor Relations:


Gateway Investor Relations
Cody Slach
Tel 1-949-574-3860
[email protected]



Nabriva Therapeutics to Report 2020 Financial Results and Recent Corporate Highlights on March 11, 2021

DUBLIN, Ireland, March 03, 2021 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its fourth quarter and full year 2020 financial results along with recent company highlights after the close of the U.S. financial markets on Thursday, March 11, 2021. Nabriva’s management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights.

The dial-in number for the conference call is 866-811-8671 for domestic participants and 409-981-0874 for international participants, with Conference ID #2689459. A live webcast of the conference call can be accessed through the “Investors” tab on the Nabriva Therapeutics website at www.nabriva.com. A replay will be available on this website shortly after conclusion of the event for 90 days.

About Nabriva Therapeutics plc

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Nabriva Therapeutics, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: Nabriva Therapeutics’ ability to successfully implement its commercialization plans for XENLETA and whether market demand for XENLETA is consistent with its expectations, Nabriva Therapeutics’ ability to build and maintain a sales force for XENLETA, the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, whether results of early clinical trials or studies in different disease indications will be indicative of the results of ongoing or future trials, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals, the availability or commercial potential of CONTEPO for the treatment of cUTI, the ability to retain and hire key personnel, the availability of adequate additional financing on acceptable terms or at all and such other important factors as are set forth in Nabriva Therapeutics’ annual and quarterly reports and other filings on file with the SEC. In addition, the forward-looking statements included in this press release represent Nabriva Therapeutics’ views as of the date of this press release. Nabriva Therapeutics anticipates that subsequent events and developments may cause its views to change. However, while Nabriva Therapeutics may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Nabriva Therapeutics’ views as of any date subsequent to the date of this press release.

CONTACTS:

For Investors

Kim Anderson
Nabriva Therapeutics plc
[email protected]

For Media

Mike Beyer
Sam Brown Inc.
[email protected]
312-961-2502



DiaMedica Therapeutics to Report Fourth Quarter 2020 Financials and Provide a Business Update March 11, 2021

DiaMedica Therapeutics to Report Fourth Quarter 2020 Financials and Provide a Business Update March 11, 2021

MINNEAPOLIS–(BUSINESS WIRE)–
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its fourth quarter 2020 financial results will be released after the markets close on Wednesday, March 10th. DiaMedica will host a live conference call on Thursday, March 11th at 7:00 AM Central Time to discuss its business update and financial results.

Conference Call details:

Date:

Thursday, March 11, 2021

Time:

7:00 AM CT / 8:00 AM ET

Web access:

https://event.on24.com/wcc/r/2948450/3CC8FC74172F3DEDB9258000144DA5E4

Dial In:

(866) 393-4306 (domestic)

(734) 385-2616 (international)

Conference ID:

9297319

Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for play back on our website, under investor events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until March 18, 2021, by dialing (855) 859-2056 (US Toll Free), (404) 537-3406 (International), replay passcode 9297319.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical stage biopharmaceutical company focused on developing novel treatments to improve the lives of patients with neurological and chronic kidney diseases. To learn more about DiaMedica, please visit www.diamedica.com.

Scott Kellen

Chief Financial Officer

Phone: (763) 496-5118

[email protected]

KEYWORDS: Minnesota United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Clinical Trials

MEDIA:

Logo
Logo

DECISION DIAGNOSTICS CORP. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a federal securities class action lawsuit has been filed against Decision Diagnostics Corp.


LEAD PLAINTIFF DEADLINE IS MARCH 16, 2021

NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP reminds all investors that a federal securities class action lawsuit was filed in the United States District Court for the Central District of California against Decision Diagnostics Corp. (“Decision Diagnostics” or “the Company”) (OTCBB: DECN) on behalf of investors who purchased the Company’s securities between March 3, 2020 and December 17, 2020, inclusive (the ”Class Period”).

All investors who purchased shares of
Decision Diagnostics Corp. and incurred losses are urged to contact the firm immediately at

[email protected]

or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action or

join the case

on our website,

www.whafh.com.

If you have incurred losses in the shares of Decision Diagnostics Corp., you may,no later than March 16, 2021, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in the shares of Decision Diagnostics Corp.


CLICK HERE TO JOIN CASE

According to the filed Complaint, the Company made false and misleading statements to the market. Decision Diagnostics failed to develop a viable COVID-19 test in any form, let alone a test that could detect the virus in less than one minute. The Company was not capable of meeting the U.S. Food and Drug Administration’s (FDA’s) EUA testing requirements for its purported COVID-19 test. Despite this inability to meet FDA requirements, the Company touted an unrealistic time to market for its tests. Based on these facts, the Company’s public statements were false and materially misleading throughout the class.

Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas, and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected], [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.



REGI INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Renewable Energy Group, Inc.

NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) — Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Renewable Energy Group, Inc. (“Renewable Energy ” or the “Company”) (NASDAQ: REGI) from May 3, 2018, through February 25, 2021 (the “Class Period”). The lawsuit filed in the United States District Court for the Southern District of New York alleges violations of the Securities Exchange Act of 1934.

If you purchased Renewable Energy securities, and/or would like to discuss your legal rights and options please visit Renewable Energy Shareholder Class Action Lawsuit or contact Matthew E. Guarnero toll free at (877) 779-1414 or [email protected]

The complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose to investors: (1) that due to failures in the diesel additive system, petroleum diesel was not periodically added to certain loads by the Company and was instead added by the Company’s customers; (2) that, as a result, Renewable Energy was not the proper claimant for certain BTC payments on biodiesel it sold between January 1, 2017 and September 30, 2020; (3) that, as a result, Renewable Energy’s revenue and net income were overstated for certain periods; (4) that there was a material weakness in the Company’s internal control over financial reporting related to the purchase and use of the petroleum diesel gallons when blending with biodiesel; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On February 25, 2021, after the market closed, Renewable Energy issued a press release announcing its fourth quarter and full year 2020 financial results. Therein, the Company revealed that it would restate “$38.2 million in cumulative revenue from January 2018 through September 30, 2020” because Renewable Energy was not the “proper claimant for certain BTC payments on biodiesel it sold between January 1, 2017 and September 30, 2020.” Renewable Energy further stated that it had reached an agreement with the Internal Revenue Service “on a $40.5 million assessment, excluding interest” to correct these claims.

On this news, the Company’s share price fell $8.17, or 9.5%, over two consecutive trading sessions to close at $77.77 per share on February 26, 2021, on unusually heavy trading volume.

If you wish to serve as lead plaintiff, you must move the Court no later than May 3, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

If you purchased Renewable Energy securities, and/or would like to discuss your legal rights and options please visit https://www.bernlieb.com/cases/renewableenergygroupinc-regi-shareholder-class-action-lawsuit-stock-fraud-371/apply/ or contact Matthew E. Guarnero toll free at (877) 779-1414 or [email protected].

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2021 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information

Matthew E. Guarnero
Bernstein Liebhard LLP
https://www.bernlieb.com
(877) 779-1414
[email protected]



Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Ontrak, Inc. (OTRK) on Behalf of Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Ontrak, Inc. (OTRK) on Behalf of Investors

LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Ontrak, Inc. (“Ontrak” or the “Company”) (NASDAQ: OTRK) investors concerning the Company’s possible violations of the federal securities laws.

If you suffered a loss on your Ontrak investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/ontrak-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

On March 1, 2021, Ontrak issued a press release announced preliminary financial results for fourth quarter and full year 2020. Therein, the Company stated that its largest customer had terminated its contract with Ontrak, effective June 26, 2021. The Company stated that this customer “evaluated Ontrak on a provider basis” and “[a]s such, the customer evaluated [Ontrak’s] performance based on [its] ability to achieve the lowest possible cost per medical visit, and not on [its] clinical outcomes data or medical cost savings.” The Company also stated that “the coaching model which Ontrak has pioneered for over a decade was seen by the customer to be less relevant to their performance metrics.”

On this news, the Company’s share price fell $27.32, or more than 46%, to close at $31.62 per share on March 1, 2021, thereby injuring investors.

Follow us for updates on LinkedIn, Twitter, or Facebook.

Whistleblower Notice: Persons with non-public information regarding Ontrak should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email [email protected].

About GPM

Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. ISS Securities Class Action Services has consistently ranked GPM in its annual SCAS Top 50 Report. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM’s nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM’s lawyers have handled cases covering a wide spectrum of corporate misconduct including cases involving financial restatements, internal control weaknesses, earnings management, fraudulent earnings guidance and forward looking statements, auditor misconduct, insider trading, violations of FDA regulations, actions resulting in FDA and DOJ investigations, and many other forms of corporate misconduct. GPM’s attorneys have worked on securities cases relating to nearly all industries and sectors in the financial markets, including, energy, consumer discretionary, consumer staples, real estate and REITs, financial, insurance, information technology, health care, biotech, cryptocurrency, medical devices, and many more. GPM’s past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron’s, Investor’s Business Daily, Forbes, and Money.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP, Los Angeles

Charles H. Linehan, 310-201-9150 or 888-773-9224

1925 Century Park East, Suite 2100

Los Angeles, CA 90067

www.glancylaw.com

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo

BlackRock Capital Investment Corporation Reports Financial Results for the Quarter Ended December 31, 2020, Declares Quarterly Cash Distribution of $0.10 per Share

BlackRock Capital Investment Corporation Reports Financial Results for the Quarter Ended December 31, 2020, Declares Quarterly Cash Distribution of $0.10 per Share

  • GAAP Net Investment Income (“NII”) of $0.10 per share, or $7.3 million, provided fourth quarter distribution coverage of 101%.
  • Net Asset Value (“NAV”) increased to $315.0 million, up 2.8% from $306.6 million; NAV per share decreased 0.2% to $4.23 per share from $4.24 per share, primarily due to an increase in total shares outstanding.
  • Transformational progress towards reducing junior capital and non-core exposure, successfully exiting $171 million of these investments during the fourth quarter and subsequent period. As a result, non-core holdings represent just 9%1 of the total portfolio at fair value as of February 23, 2021.
  • Net leverage of 0.51x as of December 31, 2020, down significantly from 0.98x as of September 30, 2020, primarily driven by net investment exits during the fourth quarter.
  • Total liquidity for portfolio company investments, including cash, was approximately $285 million, subject to leverage and borrowing base restrictions.

NEW YORK–(BUSINESS WIRE)–
BlackRock Capital Investment Corporation (NASDAQ:BKCC) (“BCIC” or the “Company,” “we,” “us” or “our”) announced today that its Board of Directors declared a quarterly distribution of $0.10 per share, payable in cash on April 7, 2021 to stockholders of record at the close of business on March 17, 2021.

“We are pleased to report continued transformational progress towards our goal of reducing non-core and junior capital exposure in our portfolio,” said James E. Keenan, Chairman and Interim CEO of the Company. “During and subsequent to the fourth quarter, we made significant headway in reducing this exposure. We achieved this primarily through meaningful reductions in our exposure to Gordon Brothers Finance Company (“GBFC”) and BCIC Senior Loan Partners (“SLP”), coupled with the complete exits of our investments in First Boston Construction Holdings (“FBCH”) and CB-HDT Holdings. In addition, we believe there are more near-term opportunities that could lead to continued repayments in the non-core book.”

 

February 23, 20211

September 30, 2020

December 31, 2019

Portfolio Composition

 

 

 

First Lien Debt

58%

37%

34%

Second Lien Debt

28%

25%

23%

Junior Capital2

14%

38%

43%

 

 

 

 

Portfolio Company Count

58

55

47

Non-Core Assets

 

 

 

Portfolio Company Count3

6

7

9

FMV ($ in Millions)

40

53

120

% of investments, at FMV

9%

9%

16%

1 Preliminary estimate of portfolio construction as of February 23, 2021, using valuation marks as of December 31, 2020.

2 Includes unsecured/subordinated debt and equity investments.

3 Excludes portfolio companies with zero fair market value.

 

October 1, 2020 – February 23, 2021

$ in Millions

%

Deployments

 

 

First Lien Debt

69

76%

Second Lien Debt

21

23%

Unsecured Debt

1

1%

Repayments/Exits

 

 

Non-Core & Junior Capital

171

68%

Other Core Assets

80

32%

“The Company has continued to identify strong risk-adjusted return opportunities for capital deployment. Consistent with our strategy, investments have been focused on senior secured debt with an emphasis on first lien loans. We expect the percentage of first lien investments as well as the diversity of the portfolio to further increase as we continue to deploy capital,” added Keenan.

“We are returning to paying an all cash dividend this quarter at a level of $0.10 per share. For the last three quarters, we have de-risked our portfolio during a period of unprecedented economic uncertainty, and as part of that process we took the prudent but temporary step of paying a portion of our dividend in stock. With most of the de-risking accomplished, we are confident in resuming our normalized approach to dividends.

“This strategic progress has resulted in significant repayments and deleveraging, causing portfolio leverage to decline to approximately 0.43x as of February 23rd, 2021, from 0.98x at the end of the third quarter of 2020. We believe the strength of our platform will allow us to rebuild the portfolio in a manner that is consistent with our strategy. In the near term, we expect that NII will likely be compressed (in the range of 5 to 6 cents per share at the current leverage ratio). We anticipate that, as we redeploy capital, we will rebuild NII, enabling us to grow into the dividend,” added Keenan.

“With the strategic portfolio exits largely behind us, our near-term priorities include optimizing our capital structure, which includes addressing the 2022 and 2023 debt maturities, as well as allocating more capital towards programmatic share repurchases. Additionally, to further bolster NAV, BlackRock has elected to fully waive its incentive fee for the fourth quarter, which totaled $1.3 million,” concluded Keenan.

Financial Highlights

 

Q4 2020

Q3 2020

Q4 2019

($’s in millions, except per share data)

Total

Amount

 

Per Share

 

Total

Amount

 

Per Share

 

Total

Amount

 

Per Share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Investment Income/(loss)

$7.3

 

$0.10

 

$8.5

 

$0.12

 

$9.6

 

$0.14

 

Net realized and unrealized gains/(losses)

$2.6

 

$0.04

 

$(35.7)

 

$(0.51)

 

$(11.2)

 

$(0.16)

 

Basic earnings/(losses)

$9.9

 

$0.14

 

$(27.2)

 

$(0.39)

 

$(1.6)

 

$(0.02)

 

Distributions declared

$7.2

 

$0.10

 

$7.0

 

$0.10

 

$9.6

 

$0.14

 

Net Investment Income/(loss), as adjusted1

$7.3

 

$0.10

 

$8.5

 

$0.12

 

$9.6

 

$0.14

 

Basic earnings/(losses), as adjusted1

$9.9

 

$0.14

 

$(27.2)

 

$(0.39)

 

$(1.6)

 

$(0.02)

 

 

2020 Totals

2019 Totals

($’s in millions, except per share data)

Total Amount

 

Per Share

 

Total Amount

 

Per Share

 

 

 

 

 

 

 

 

 

 

Net Investment Income/(loss)

$34.2

 

$0.49

 

$41.9

 

$0.61

 

Net realized and unrealized gains/(losses)

$(138.1)

 

$(1.98)

 

$(48.8)

 

$(0.71)

 

Basic earnings/(losses)

$(103.9)

 

$(1.49)

 

$(6.9)

 

$(0.10)

 

Distributions declared

$30.6

 

$0.44

 

$44.1

 

$0.64

 

Net Investment Income/(loss), as adjusted1

$34.2

 

$0.49

 

$41.9

 

$0.61

 

Basic earnings/(losses), as adjusted1

$(103.9)

 

$(1.49)

 

$(6.9)

 

$(0.10)

 

($’s in millions, except per share data)

December 31, 2020

September 30, 2020

December 31, 2019

 

 

 

 

Total assets

$511.7

$621.4

$774.1

Investment portfolio, at fair market value

$479.0

$609.0

$749.9

Debt outstanding

$179.8

$305.0

$313.6

Total net assets

$315.0

$306.6

$435.6

Net asset value per share

$4.23

$4.24

$6.33

Net leverage ratio2

0.51x

0.98x

0.70x

______________________________________

1 Non-GAAP basis financial measure. See Supplemental Information on page 10.

2 Calculated as the ratio between (A) debt, excluding unamortized debt issuance costs, less available cash and receivable for investments sold, plus payables for investments purchased, and (B) NAV.

Business Updates for the Fourth Quarter and Subsequent Period

  • Reduced Exposure in Non-core Legacy Portfolio:
    • Our investment in the unsecured debt of CB-HDT Holdings, Inc. was repaid in full (along with the entire accrued and unpaid PIK interest), resulting in a repayment of $9.4 million to the Company. This investment had a FMV of $8.9 million at September 30, 2020.
    • Red Apple Stores Inc. paid down $6.2 million on its 2nd lien loan to the Company utilizing excess cash on its balance sheet as its financial performance improved significantly during 2020. The FMV of the remaining 2nd lien investment in Red Apple is $14.8 million as of December 31, 2020. This investment had a FMV of $17.3 million at September 30, 2020, which was prior to the aforementioned principal reduction.
    • As of February 23rd, 2021, non-core legacy assets comprised approximately $40 million, or 9% of our total portfolio at fair market value (six portfolio companies), as compared to 9% at the end of the third quarter and 16% at the end of 2019. Of the $40 million, approximately $38 million of non-core positions at FMV consist of income-producing investments across five portfolio companies.
  • Reduced Exposure in other junior capital:
    • During the fourth quarter, $87.4 million of repayments were received on the unsecured debt of GBFC. These repayments were driven by (i) the previously disclosed sale of GBFC’s loan portfolio to Callodine Commercial Finance, Inc. and (ii) monetization of an equity warrant position issued by a prior GBFC portfolio company. The FMV of the Company’s remaining unsecured debt of GBFC is $22.9 million as December 31, 2020. This investment had an FMV of $121.8 million at September 30, 2020 which was prior to the aforementioned loan portfolio sale.
    • SLP sold a majority of its loan portfolio in the fourth quarter. Following this sale, SLP paid off and terminated its credit facility, and returned $23.0 million of capital to BCIC in December. Subsequent to year end, SLP partially sold one additional investment and returned an incremental $4 million to BCIC. After these sales, the remaining portfolio of SLP now consists of four portfolio companies with first lien loans with an aggregate FMV of approximately $31 million. BCIC owns 85% of the equity in SLP.
    • Investments in the subordinated debt and equity of First Boston Construction Holdings, LLC were fully repaid subsequent to the end of the fourth quarter resulting in the payment of $38.5 million to the Company. These investments had a FMV of $37.2 million at December 31, 2020.
  • Share Repurchase Program: No shares were repurchased under our existing share repurchase program during the fourth quarter of 2020. Cumulative repurchases since BlackRock entered into the investment management agreement with the Company in early 2015 total approximately 8.3 million shares for $54.0 million. Since the inception of our share repurchase program through December 31, 2020, we have purchased over 10.0 million shares at an average price of $6.62 per share, including brokerage commissions, for a total of $66.3 million. On November 3, 2020, the Company’s Board of Directors authorized the Company to purchase up to a total of 7,500,000 shares, effective until the earlier of November 2, 2021 or such time that all the authorized shares have been repurchased. As of December 31, 2020, 7,500,000 shares remained authorized for repurchase. With several strategic portfolio exits already accomplished, BCIC is increasing the amount of capital allocated towards programmatic share repurchases.

Fourth Quarter Financial Updates

  • NII was $7.3 million, or $0.10 per share, for the three months ended December 31, 2020. Relative to distributions declared of $0.10 per share, our NII distribution coverage was 101% for the quarter. Total investment income declined by 10.4% compared to previous quarter mainly driven by GBFC unsecured debt being put on non-accrual status during the fourth quarter.
  • NAV increased to $315.0 million, up 2.8% from $306.6 million as of September 30, 2020. NAV per share decreased 0.2% or $(0.01) per share to $4.23 per share on a quarter-over-quarter basis, primarily due to an increase in total shares outstanding.
  • For the quarter ended December 31, 2020, we incurred base management fees of $2.3 million, and incentive management fees based on income of $1.3 million. Our advisor has voluntarily waived the incentive fees based on income of $1.3 million, resulting in no net incentive fees for the period. Since March 2017, the adviser has waived $29.7 million of incentive management fees on a cumulative basis. For incentive management fees based on gains, there was no accrual or payment as of December 31, 2020.
  • Tax characteristics of all 2020 distributions were reported to stockholders on Form 1099 after the end of the calendar year. Our 2020 distributions included a $0.12 per share return of capital. Our return of capital distributions totaled $2.11 per share from inception to December 31, 2020. At our discretion, we may carry forward taxable income in excess of calendar year distributions and pay a 4% excise tax on this income. We will accrue excise tax on estimated undistributed taxable income as required. There was no undistributed taxable income carried forward from 2020.

Portfolio and Investment Activity for the Fourth Quarter and Subsequent Period*

($’s in millions)

Three Months

Ended

December 31,

2020

Three Months

Ended

December 31,

2019

Year

Ended

December 31,

2020

Year

Ended

December 31,

2019

 

 

 

 

 

 

 

 

 

Investment deployments

$59.9

 

$73.0

 

$143.5

 

$303.5

 

Investment exits

$193.2

 

$38.1

 

$277.6

 

$176.7

 

Number of portfolio company investments at the end of period

55

 

47

 

55

 

47

 

Weighted average yield of debt and income producing equity securities, at fair market value

8.9%

 

10.9%

 

8.9%

 

10.9%

 

% of Portfolio invested in Secured debt, at fair market value

77%

 

57%

 

77%

 

57%

 

% of Portfolio invested in Unsecured debt, at fair market value

13%

 

22%

 

13%

 

22%

 

% of Portfolio invested in Equity, at fair market value

10%

 

21%

 

10%

 

21%

 

Average investment by portfolio company, at amortized cost

(excluding investments below $5.0 million)

$17.3

 

$21.9

 

$17.3

 

$21.9

 

*Balance sheet amounts and yield information above are as of period end

  • We deployed $59.9 million during the quarter while exits and repayments totaled $193.2 million, resulting in a $133.3 million net decrease in our portfolio primarily due to progress made in reducing exposure in non-core and other junior capital investments previously mentioned.

    • Our deployments primarily consisted of seven new portfolio companies and three investments into existing portfolio companies, which are outlined as follows:

      • New Portfolio Companies
        • $25.0 million L + 9.00% first lien term loan and $8.1 million unfunded delayed draw term loan to Callodine Commercial Finance, LLC, as part of the previously disclosed GBFC transaction;
        • $7.8 million L + 6.25% first lien term loan to Paula’s Choice Holdings, Inc., a well-established direct-to-consumer skincare brand;
        • $5.8 million L + 9.00% second lien term loan to Team Services Group, LLC, a leading provider of homecare assistance for the elderly and people with disabilities;
        • $4.7 million L + 7.00% first lien term loan and $3.1 million unfunded delayed draw term loan to Thras.io, LLC, a consolidator of small to medium sized brands that sell through Amazon’s third-party platform;
        • $4.7 million L + 8.00% second lien term loan to Syndigo, LLC, a provider of digital content and retail optimization solutions for the consumer goods industry;
        • $1.8 million L + 6.25% first lien term loan and $0.3 million revolving term loan ($0.1 million unfunded) to IT Parent, LLC, a sales automation software platform designed for insurance carriers and distributors; and
        • $1.5 million L + 7.00% first lien term loan and $3.5 million unfunded delayed draw term loan to Sonny’s Enterprises, LLC, a manufacturer and provider of car wash equipment, parts, chemicals and controls software;
      • Incremental Investments
        • $3.0 million of incremental L + 6.76% first lien term loan to Live Auctioneers, LLC;
        • $2.3 million of incremental L + 8.50% second lien term loan to AmeriLife Holdings, LLC; and
        • $1.3 million of incremental L + 7.00% second lien term loan to NEP II, Inc.
    • Our sales, exits, and repayments were primarily concentrated in seven portfolio company exits, three partial repayments, two partial sales, and one partial return of capital:

      • $87.4 million partial repayment of our unsecured debt in GBFC;
      • $23.0 million partial return of capital from our equity investment in SLP;
      • $17.5 million full repayment of Vertellus Holdings, LLC first lien term loan;
      • $11.9 million full repayment of Cambrex Corporation second lien term loan;
      • $9.4 million full repayment of CB-HDT Holdings, Inc. unsecured debt, a non-core legacy position;
      • $9.1 million of proceeds from our partial sale of Zest Acquisition Corp. second lien term loan;
      • $8.4 million full repayment of P&L Development, LLC first lien term loan;
      • $6.2 million partial repayment of Red Apple Stores Inc. second lien term loan, a non-core legacy position;
      • $5.1 million full repayment of ECI Macola/Max Holding, LLC second lien term loan;
      • $4.9 million of proceeds from our partial sale of Midwest Physician Administrative Services, LLC second lien term loan;
      • $3.5 million partial repayment of Outcomes Group Holdings, Inc. second lien term loan;
      • $2.7 million full repayment of Pulse Secure, LLC first lien term loan; and
      • $2.4 million full repayment of Marketlive, LLC (Kibo) first lien term loan.
  • As of December 31, 2020, there were four non-accrual investment positions, representing approximately 6.5% and 17.8% of total debt and preferred stock investments, at fair value and cost, respectively, as compared to four non-accrual investment positions of approximately 2.4% and 6.9% of total debt and preferred stock investments at fair value and cost, respectively, at December 31, 2019. As previously disclosed, the Company’s unsecured debt investment in GBFC became a new non-accrual investment during the quarter after the sale of GBFC’s loan portfolio. As described earlier, the remaining investment stands to benefit from recovery on the interests retained by GBFC. The average internal investment rating of the portfolio at fair market value at December 31, 2020 was 1.90 as compared to 1.78 as of the prior quarter end. As of February 23, 2021, there were three non-accrual investment positions, representing approximately 5.4% of total debt and preferred stock investments, at fair value.
  • During the quarter ended December 31, 2020, net realized and unrealized gains were $2.6 million, primarily attributable to net appreciation in portfolio valuations during the quarter.

Liquidity and Capital Resources

  • At December 31, 2020, we had $23.3 million in cash and cash equivalents and $261.2 million of availability under our credit facility, subject to leverage restrictions, resulting in approximately $284.5 million of availability for portfolio company investments. Committed but unfunded portfolio obligations at December 31, 2020 were $20.0 million (excluding the $4.2 million LP commitment to SLP, which is completely discretionary). We believe there is sufficient liquidity to meet all of the Company’s obligations and selectively deploy new capital.
  • Net leverage, adjusted for available cash, receivables for investments sold, payables for investments purchased and unamortized debt issuance costs, was 0.51x at quarter-end, and our 271% asset coverage ratio provided the Company with available debt capacity under its asset coverage requirements of $220.7 million. As of February 23, 2021, after accounting for portfolio activity subsequent to the quarter, net leverage declined to approximately 0.43x. Further, as of December 31, 2020, approximately 82% of our assets were invested in qualifying assets, exceeding the 70% regulatory requirement of a business development company.
  • On December 30, 2020, the Company paid a dividend of $0.10 per share, or $7.23 million, to stockholders of record on November 18, 2020, as announced on November 4, 2020. Of the total $7.23 million dividend, approximately $1.45 million was paid in cash and $5.78 million was paid in approximately 2.16 million shares of the Company’s common stock issued at a price of $2.684 per share (representing the average closing stock price for the Company’s stock on the five trading days beginning on December 16, 2020 and ending on December 22, 2020 (both days inclusive)). Due to the portion of dividends paid in common stock, our NAV has increased by approximately $5.78 million on December 30, 2020.
  • For the first quarter of 2021, BCIC declared an all cash dividend of $0.10 per share, payable on April 7, 2021 to stockholders of record at the close of business on March 17, 2021.

Conference Call

BlackRock Capital Investment Corporation will host a webcast/teleconference at 10:00 a.m. (Eastern Time) on Thursday, March 4, 2021, to discuss its fourth quarter 2020 financial results. All interested parties are welcome to participate. You can access the teleconference by dialing, from the United States, (800) 458-4121 or from outside the United States, +1(313) 209-6672, 10 minutes before 10:00 a.m. and referencing the BlackRock Capital Investment Corporation Conference Call (ID Number 8535673). A live, listen-only webcast will also be available via the Investor Relations section of www.blackrockbkcc.com. This teleconference can also be accessed using Microsoft Edge, Google Chrome, or Firefox via this link: BlackRock Capital Investment Corporation Fourth Quarter 2020 Earnings Call. Once clicked-on, please enter your information to be connected. Please note that the link becomes active fifteen minutes prior to the scheduled start time.

Both the teleconference and webcast will be available for replay by 1:00 p.m. on Thursday, March 4, 2021 and ending at 1:00 p.m. on Thursday, March 18, 2021. To access the replay of the teleconference, callers from the United States should dial (888) 203-1112 and callers from outside the United States should dial +1(719) 457-0820 and enter the Conference ID Number 8535673. To access the webcast, please visit the investor relations section of www.blackrockbkcc.com.

Prior to the webcast/teleconference, an investor presentation that complements the earnings conference call will be posted to BlackRock Capital Investment Corporation’s website within the Presentations section of the Investors page (https://www.blackrockbkcc.com/investors/news-and-events/disclaimer).

About BlackRock Capital Investment Corporation

BlackRock Capital Investment Corporation is a business development company that provides debt and equity capital to middle-market companies.

The Company’s investment objective is to generate both current income and capital appreciation through debt and equity investments. We invest primarily in middle-market companies in the form of senior debt securities and loans, and our investment portfolio may include junior secured and unsecured debt securities and loans, each of which may include an equity component.

BlackRock Capital Investment Corporation

Consolidated Statements of Assets and Liabilities

 

December 31, 2020

December 31, 2019

Assets

 

 

 

 

Investments at fair value:

 

 

 

 

Non-controlled, non-affiliated investments (cost of $369,079,320 and

$389,156,775)

$354,957,936

 

$377,136,394

 

Non-controlled, affiliated investments (cost of $20,927,907 and

$65,825,475)

13,099,313

 

22,473,524

 

Controlled investments (cost of $216,768,227 and $400,561,551)

110,968,227

 

350,249,163

 

Total investments at fair value (cost of $606,775,454 and

$855,543,801)

479,025,476

 

749,859,081

 

Cash and cash equivalents

23,332,831

 

14,678,878

 

Receivable for investments sold

5,439,507

 

1,871,435

 

Interest, dividends and fees receivable

2,138,304

 

5,708,324

 

Prepaid expenses and other assets

1,783,472

 

1,945,709

 

Total Assets

$511,719,590

 

$774,063,427

 

Liabilities

 

 

 

 

Debt (net of deferred financing costs of $1,360,356 and $2,298,004)

$179,798,037

 

$313,569,694

 

Interest and credit facility fees payable

502,682

 

757,472

 

Distributions payable

 

9,637,075

 

Base management fees payable

2,313,447

 

3,251,194

 

Incentive management fees payable

1,849,597

 

1,849,597

 

Payable for investments purchased

9,193,917

 

7,312,500

 

Accrued administrative services

389,064

 

372,407

 

Other accrued expenses and payables

2,662,569

 

1,704,507

 

Total Liabilities

196,709,313

 

338,454,446

 

Net Assets

 

 

 

 

Common stock, par value $.001 per share, 200,000,000 common shares

authorized, 84,478,251 and 77,861,287 issued and 74,466,665 and

68,836,255 outstanding

84,478

 

77,861

 

Paid-in capital in excess of par

866,720,809

 

849,240,398

 

Distributable earnings (losses)

(485,498,151)

 

(351,040,023)

 

Treasury stock at cost, 10,011,586 and 9,025,032 shares held

(66,296,859)

 

(62,669,255)

 

Total Net Assets

315,010,277

 

435,608,981

 

Total Liabilities and Net Assets

$511,719,590

 

$774,063,427

 

Net Asset Value Per Share

$4.23

 

$6.33

 

BlackRock Capital Investment Corporation

Consolidated Statements of Operations

 

 

Three Months

Ended

December 31,

2020

(Unaudited)

 

Three Months

Ended

December 31,

2019

(Unaudited)

 

Year

Ended

December 31,

2020

 

Year

Ended

December 31,

2019

Investment Income:

 

 

 

 

 

 

 

 

Non-controlled, non-affiliated investments:

 

 

 

 

 

 

 

 

Cash interest income

 

$8,160,377

 

$8,370,290

 

$31,426,192

 

$29,292,857

PIK interest income

 

1,268,636

 

1,226,151

 

5,026,084

 

2,085,016

Fee income

 

543,312

 

89,829

 

620,705

 

1,444,113

Total investment income from non-controlled, non-

affiliated investments

 

9,972,325

 

9,686,270

 

37,072,981

 

32,821,986

Non-controlled, affiliated investments:

 

 

 

 

 

 

 

 

Cash interest income

 

117,138

 

128,895

 

474,862

 

3,493,487

PIK interest income

 

121,049

 

116,575

 

461,367

 

245,197

PIK dividend income

 

 

 

 

220,480

Fee income

 

(7,377)

 

1,451

 

(3,055)

 

3,055

Total investment income from non-controlled, affiliated investments

 

230,810

 

246,921

 

933,174

 

3,962,219

Controlled investments:

 

 

 

 

 

 

 

 

Cash interest income

 

3,184,893

 

5,105,807

 

19,794,470

 

22,832,830

PIK interest income

 

 

759,254

 

1,053,664

 

2,776,671

Cash dividend income

 

1,220,030

 

3,389,999

 

8,190,499

 

15,562,959

Fee income

 

3,186

 

3,186

 

70,712

 

131,485

Total investment income from controlled investments

 

4,408,109

 

9,258,246

 

29,109,345

 

41,303,945

Other income

 

 

 

 

30,371

Total investment income

 

14,611,244

 

19,191,437

 

67,115,500

 

78,118,521

Expenses:

 

 

 

 

 

 

 

 

Base management fees

 

2,313,447

 

3,251,193

 

10,799,832

 

12,425,101

Incentive management fees

 

1,278,947

 

2,122,796

 

6,304,333

 

8,751,521

Interest and credit facility fees

 

3,344,257

 

4,091,942

 

15,584,214

 

15,558,648

Professional fees

 

432,544

 

309,728

 

1,964,252

 

2,093,064

Administrative services

 

389,064

 

372,407

 

1,457,979

 

1,403,419

Director fees

 

157,500

 

176,500

 

652,250

 

729,750

Investment advisor expenses

 

87,500

 

87,500

 

350,000

 

350,000

Other

 

578,667

 

288,190

 

2,083,486

 

1,800,932

Total expenses, before incentive management fee waiver

 

8,581,926

 

10,700,256

 

39,196,346

 

43,112,435

Incentive management fee waiver

 

(1,278,947)

 

(1,145,894)

 

(6,304,333)

 

(6,901,924)

Expenses, net of incentive management fee waiver

 

7,302,979

 

9,554,362

 

32,892,013

 

36,210,511

Net Investment Income

 

7,308,265

 

9,637,075

 

34,223,487

 

41,908,010

 

 

 

 

 

 

 

 

 

Realized and Unrealized Gain (Loss):

 

 

 

 

 

 

 

 

Net realized gain (loss):

 

 

 

 

 

 

 

 

Non-controlled, non-affiliated investments

 

(612,107)

 

(264,342)

 

(12,941,524)

 

(23,660,181)

Non-controlled, affiliated investments

 

(77,952)

 

(879,673)

 

(43,851,965)

 

(1,225,060)

Controlled investments

 

 

 

(59,194,744)

 

Net realized gain (loss)

 

(690,059)

 

(1,144,015)

 

(115,988,233)

 

(24,885,241)

Net change in unrealized appreciation (depreciation) on:

 

 

 

 

 

 

 

 

Non-controlled, non-affiliated investments

 

5,978,376

 

953,491

 

(2,123,600)

 

21,084,787

Non-controlled, affiliated investments

 

848,530

 

(1,733,802)

 

35,523,356

 

(24,529,889)

Controlled investments

 

(3,870,607)

 

(9,423,322)

 

(55,623,040)

 

(20,798,389)

Foreign currency translation

 

325,302

 

136,690

 

135,427

 

333,982

Net change in unrealized appreciation (depreciation)

 

3,281,601

 

(10,066,943)

 

(22,087,857)

 

(23,909,509)

Net realized and unrealized gain (loss)

 

2,591,542

 

(11,210,958)

 

(138,076,090)

 

(48,794,750)

Net Increase (Decrease) in Net Assets Resulting from Operations

 

$9,899,807

 

$(1,573,883)

 

$(103,852,603)

 

$(6,886,740)

Net Investment Income Per Share—basic

 

$0.10

 

$0.14

 

$0.49

 

$0.61

Earnings (Loss) Per Share—basic

 

$0.14

 

$(0.02)

 

$(1.49)

 

$(0.10)

Average Shares Outstanding—basic

 

72,358,355

 

68,836,255

 

69,801,849

 

68,836,590

Net Investment Income Per Share—diluted

 

$0.10

 

$0.14

 

$0.49

 

$0.59

Earnings (Loss) Per Share—diluted

 

$0.14

 

$(0.02)

 

$(1.49)

 

$(0.10)

Average Shares Outstanding—diluted

 

89,352,092

 

85,829,992

 

86,795,585

 

85,830,326

Distributions Declared Per Share

 

$0.10

 

$0.14

 

$0.44

 

$0.64

Supplemental Information

The Company reports its financial results on a generally accepted accounting principles (“GAAP”) basis; however, management believes that evaluating the Company’s ongoing operating results may be enhanced if investors have additional non-GAAP basis financial measures. Management reviews non-GAAP financial measures to assess ongoing operations and, for the reasons described below, considers them to be effective indicators, for both management and investors, of the Company’s financial performance over time. The Company’s management does not advocate that investors consider such non-GAAP financial measures in isolation from, or as a substitute for, financial information prepared in accordance with GAAP.

Incentive management fees based on income have been calculated for each calendar quarter and are paid on a quarterly basis if certain thresholds are met. The Company records its liability for incentive management fees based on capital gains by performing a hypothetical liquidation at the end of each reporting period. The accrual of this hypothetical capital gains incentive management fee is required by GAAP, but it should be noted that a fee so calculated and accrued is not due and payable until the end of the measurement period, or every June 30. The incremental incentive management fees disclosed for a given period are not necessarily indicative of actual full year results. Changes in the economic environment, financial markets and other parameters used in determining such estimates could cause actual results to differ and such differences could be material. For the period July 1, 2019 through December 31, 2020, BCIA had voluntarily and partially waived incentive fees. For a more detailed description of the Company’s incentive management fee, please refer to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, on file with the Securities and Exchange Commission (“SEC”).

Computations for the periods below are derived from the Company’s financial statements as follows:

 

Three Months

Ended

December 31,

2020

Three Months

Ended

December 31,

2019

Year Ended

December 31,

2020

Year Ended

December 31,

2019

GAAP Basis:

 

 

 

 

 

 

 

 

Net Investment Income

$7,308,265

 

$9,637,075

 

$34,223,487

 

$41,908,010

 

Net Investment Income per share

0.10

 

0.14

 

0.49

 

0.61

 

Addback: GAAP incentive management fee expense

based on Gains

 

 

 

 

Addback: GAAP incentive management fee expense

based on Income net of incentive management fee waiver

 

976,902

 

 

1,849,597

 

Pre-Incentive Fee1:

 

 

 

 

 

 

 

 

Net Investment Income

$7,308,265

 

$10,613,977

 

$34,223,487

 

$43,757,607

 

Net Investment Income per share

0.10

 

0.15

 

0.49

 

0.64

 

Less: Incremental incentive management fee expense

based on Income net of incentive management fee waiver

 

(976,902)

 

 

(1,849,597)

 

As Adjusted2:

 

 

 

 

 

 

 

 

Net Investment Income

$7,308,265

 

$9,637,075

 

$34,223,487

 

$41,908,010

 

Net Investment Income per share

0.10

 

0.14

 

0.49

 

0.61

 

Note: The NII amounts for the three months and year ended December 31, 2020 are net of incentive management fees based on income and an incentive management fee waiver in the amount of $1,278,947 and $6,304,333, respectively. Additionally, please note that the NII amounts for the three months and year ended December 31, 2019 are net of incentive management fees based on income and a corresponding incentive management fee waiver in the amounts of $1,145,894 and $6,901,924, respectively. For the periods shown, there is no difference between the GAAP and as adjusted figures; however, there may be a difference in future periods.

1 Pre-Incentive Fee: Amounts are adjusted to remove all incentive management fees. Such fees are calculated but not necessarily due and payable at this time.

2 As Adjusted: Amounts are adjusted to remove the incentive management fee expense based on gains, as required by GAAP, and to include only the incremental incentive management fee expense based on Income. Incentive management fee expense based on income has been calculated for each calendar quarter and may be paid on a quarterly basis if certain thresholds are met. Amounts reflect the Company’s ongoing operating results and reflect the Company’s financial performance over time.

Forward-looking statements

This press release, and other statements that BlackRock Capital Investment Corporation may make, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act, with respect to BlackRock Capital Investment Corporation’s future financial or business performance, strategies or expectations. Forward-looking statements are typically identified by words or phrases such as “trend,” “potential,” “opportunity,” “pipeline,” “believe,” “comfortable,” “expect,” “anticipate,” “current,” “intention,” “estimate,” “position,” “assume,” “outlook,” “continue,” “remain,” “maintain,” “sustain,” “seek,” “achieve,” and similar expressions, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may” or similar expressions.

BlackRock Capital Investment Corporation cautions that forward-looking statements are subject to numerous assumptions, risks and uncertainties, which may change over time. Forward-looking statements speak only as of the date they are made, and BlackRock Capital Investment Corporation assumes no duty to and does not undertake to update forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements and future results could differ materially from historical performance.

In addition to factors previously disclosed in BlackRock Capital Investment Corporation’s SEC reports and those identified elsewhere in this press release, the following factors, among others, could cause actual results to differ materially from forward-looking statements or historical performance: (1) our future operating results; (2) our business prospects and the prospects of our portfolio companies; (3) the impact of investments that we expect to make; (4) our contractual arrangements and relationships with third parties; (5) the dependence of our future success on the general economy and its impact on the industries in which we invest; (6) the financial condition of and ability of our current and prospective portfolio companies to achieve their objectives; (7) our expected financings and investments; (8) the adequacy of our cash resources and working capital, including our ability to obtain continued financing on favorable terms; (9) the timing of cash flows, if any, from the operations of our portfolio companies; (10) the impact of increased competition; (11) the ability of our investment advisor to locate suitable investments for us and to monitor and administer our investments; (12) potential conflicts of interest in the allocation of opportunities between us and other investment funds managed by our investment advisor or its affiliates; (13) the ability of our investment advisor to attract and retain highly talented professionals; (14) changes in law and policy accompanying the new administration and uncertainty pending any such changes; (15) increased geopolitical unrest, terrorist attacks or acts of war, which may adversely affect the general economy, domestic and local financial and capital markets, or the specific industries of our portfolio companies; (16) changes and volatility in political, economic or industry conditions, the interest rate environment, foreign exchange rates or financial and capital markets; (17) the unfavorable resolution of legal proceedings; and (18) the impact of changes to tax legislation and, generally, our tax position.

BlackRock Capital Investment Corporation’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC identifies additional factors that can affect forward-looking statements.

Available Information

BlackRock Capital Investment Corporation’s filings with the SEC, press releases, earnings releases and other financial information are available on its website at www.blackrockbkcc.com. The information contained on our website is not a part of this press release.

Investors:

Nik Singhal

212.810.5427

Press:

Brian Beades

212.810.5596

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Splunk Inc. Announces Fiscal Fourth Quarter and Full Year 2021 Financial Results

Splunk Inc. Announces Fiscal Fourth Quarter and Full Year 2021 Financial Results

Cloud ARR Growth Accelerates to 83%; Total ARR up 41%

SAN FRANCISCO–(BUSINESS WIRE)–Splunk Inc. (NASDAQ: SPLK), provider of the Data-to-Everything Platform, today announced results for its fiscal fourth quarter and full year ended January 31, 2021.

Fourth Quarter 2021 Financial Highlights

  • Cloud ARR was $810 million, up 83% year-over-year.
  • Total ARR was $2.36 billion, up 41% year-over-year.
  • Cloud revenue was $171 million, up 72% year-over-year.
  • Total revenues were $745 million, down 6% year-over-year.
  • 510 customers with ARR greater than $1 million, up 44% year-over-year.

Full Year 2021 Financial Highlights

  • Cloud revenue was $554 million, up 77% year-over-year.
  • Total revenues were $2.23 billion, down 5% year-over-year.
  • GAAP operating loss was $780 million; GAAP operating margin was negative 35%.
  • Non-GAAP operating loss was $85 million; non-GAAP operating margin was negative 3.8%.
  • GAAP loss per share was $5.68; non-GAAP loss per share was $0.55.
  • Operating cash flow was negative $191 million with free cash flow of negative $228 million.

“Just three years ago, we set out to radically transform Splunk to better help our customers put data at the heart of their own organizations and strategy,” said Doug Merritt, President and CEO, Splunk. “I’ve been incredibly proud of our progress through our transformation, and this quarter’s performance is no exception.”

“The market’s demand for data-driven solutions that enable digital and cloud transformation has never been higher,” Merritt continued. “We now have more than 500 customers investing over $1 million annually in our platform and solutions. At our size, Splunk is one of the fastest growing companies in the history of enterprise software.”

“With Total ARR growing 41% year-over-year and $810M of Cloud ARR accelerating to 83% growth, we are extremely proud of the team’s execution and the company’s business fundamentals, both of which remain strong,” said Jason Child, chief financial officer, Splunk. “As organizations continue to reinvent towards the cloud, I’m confident that our ability to support them across IT, Security and Developer operations positions Splunk for long-term success.”

Fiscal Year 2021 & Recent Business Highlights:

New and Expansion Customers Include: California Pizza Kitchen, Cornerstone OnDemand, Europcar (France), Ghana International Bank, Lockheed Martin Space, Nationwide Building Society (United Kingdom), NATO Communications and Information Agency (Belgium), The New York City Fire Department (FDNY), Nvidia, Okta, Shopify, Strava, Tesco (United Kingdom), Tide, United States Census Bureau

  • Splunk’s Data-to-Everything Platform Helps Customers Thrive in the Data Age: New enhancements to Splunk Cloud and Splunk Enterprise power Splunk’s Data-to-Everything Platform, allowing customers to bring data to every decision, question and action across IT, Security and Observability. With updates to Splunk Data Stream Processor,Splunk Connected Experiences and Splunk’s Machine Learning Environment (SMLE), organizations around the world can improve the speed, scale and flexibility of Splunk, with new search and mobile capabilities that enable faster cloud transformation.
  • Splunk’s Industry-Leading IT & Security Platforms Accelerate the Cloud Journey: Splunk announced a series of cloud-centric updates to its market-shaping IT and Security offerings, Splunk IT Service Intelligence (ITSI) and Splunk Enterprise Security. New updates to Splunk Mission Control helps security teams unify and modernize security operations in the cloud; while the latest version of Splunk IT Service Intelligence gives teams end-to-end visibility, operational efficiency and business intelligence so organizations can predict incidents before they impact customers.
  • Splunk Customers Go All-In On Cloud: Parallel to Splunk’s significant Cloud products transformation, businesses using Splunk around the world are embracing Splunk Cloud to modernize their data strategies and embrace The Data Age. Across 2020, Splunk’s cloud business represented nearly half of the company’s software bookings, enabling organizations to migrate workloads and applications to the cloud, manage colossal spikes in data volume or increase visibility into cloud security risks.
  • Splunk Launches the World’s Most Comprehensive Observability Suite: Announced at .conf20, Splunk’s Observability Suite combines the power of Splunk’s Data-to-Everything Platform with acquired technologies including SignalFx, Ominition, Streamlio, Plumbr, Rigor and Flowmill. By aligning best-in-class solutions for infrastructure monitoring, application performance monitoring, digital experience monitoring, log investigation and incident response into a single, tightly integrated suite of products, Splunk’s Observability Suite helps IT and DevOps teams tackle new monitoring challenges that other tools simply can’t effectively address.
  • Splunk’s World-Renowned Partners Help Fuel Digital Transformation Initiatives: Spawned by the world’s rapidly accelerating shift to the cloud, Splunk’s Splunk Partner+ ecosystem continued to expand, helping customers bring data to everything. This year, Splunk Cloud launched on Google Cloud, helping organizations achieve actionable insights from their data that enable fast decisions and real-time visibility across the enterprise. Splunk also built on its strong partnership and demonstrated increased mutual investment and resourcing with AWS by signing a new 3-year strategic collaboration agreement.
  • Splunk Recognized Globally as a Career-Defining, Destination Workplace: In spite of the ongoing COVID-19 pandemic, Splunk continued to grow its global workforce to over 6,000 Splunkers, united in one mission to turn data into doing. Throughout the year, the company was recognized as a leader in corporate culture, being named by Fortune as a Most Admired Company, Future 50 Company, Best Workplace for Women and Best Workplace for Millennials, amongst other technology and workplace awards.

Financial Outlook

The company is providing the following guidance for its fiscal first quarter 2022 (ending April 30, 2021):

  • Total ARR is expected to be between $2.42 billion and $2.44 billion.
  • Total revenues are expected to be between $480 million and $500 million.
  • Non-GAAP operating margin is expected to be approximately negative 30%.

All forward-looking non-GAAP financial measures contained in this section “Financial Outlook” exclude estimates for stock-based compensation and related employer payroll tax, acquisition-related adjustments, amortization of intangible assets and capitalized software costs.

A reconciliation of non-GAAP guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty regarding, and the potential variability of, many of these costs and expenses that may be incurred in the future. The company has provided a reconciliation of GAAP to non-GAAP financial measures in the financial statement tables for its fiscal fourth quarter and full year 2021 non-GAAP results included in this press release.

Conference Call and Webcast

Splunk’s executive management team will host a conference call today beginning at 1:30 p.m. PT (4:30 p.m. ET) to discuss the company’s financial results and business highlights. Interested parties may access the call by dialing (866) 501-1535. International parties may access the call by dialing (216) 672-5582. A live audio webcast of the conference call will be available through Splunk’s Investor Relations website at http://investors.splunk.com/events-presentations. A replay of the call will be available through March 10, 2021 by dialing (855) 859-2056 and referencing Conference ID 1086748.

Safe Harbor Statement

This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding Splunk’s total ARR, revenue and non-GAAP operating margin targets for the company’s fiscal first quarter in the paragraphs under “Financial Outlook” above and other statements regarding our market opportunity, including the impact of the COVID-19 pandemic on the business environment, such as the pace of customer digital and cloud transformation and the importance of data; the growth of our cloud business; the market for data-related products and trends in this market, future growth and related targets, including trends in our cloud software business mix, customer renewals, momentum, growth rate, strategy, technology and product innovation; expectations for our industry and business, such as our business model, customer demand, our partner relationships, customer success and feedback, expanding use of Splunk by customers, and expected benefits and scale of our products. There are a significant number of factors that could cause actual results to differ materially from statements made in this press release, including: risks associated with Splunk’s rapid growth, particularly outside of the United States; Splunk’s inability to realize value from its significant investments in its business, including product and service innovations and through acquisitions; Splunk’s shift from sales of perpetual licenses in favor of sales of term licenses and subscription agreements for our cloud services which impact the timing of revenue, cash collections and margins; a shift from sales of term licenses in favor of sales of subscription agreements for our cloud services which impact the timing of revenue and margins; Splunk’s transition to a multi-product software and services business; Splunk’s inability to successfully integrate acquired businesses and technologies, such as Plumbr, Rigor and Flowmill; Splunk’s inability to service its debt obligations or other adverse effects related to our convertible notes; the impact of the COVID-19 pandemic and related public health measures on our business, as well as the impact of the COVID-19 pandemic on the overall economic environment, including customer buying capacity, urgency and patterns; and general market, political, economic, business and competitive market conditions.

Additional information on potential factors that could affect Splunk’s financial results is included in the company’s Quarterly Report on Form 10-Q for the fiscal quarter ended October 31, 2020, which is on file with the U.S. Securities and Exchange Commission (“SEC”) and Splunk’s other filings with the SEC. Splunk does not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

About Splunk Inc.

Splunk Inc. (NASDAQ: SPLK) turns data into doing with the Data-to-Everything Platform. Splunk technology is designed to investigate, monitor, analyze and act on data at any scale.

Splunk, Splunk>, Data-to-Everything, D2E and Turn Data Into Doing are trademarks and registered trademarks of Splunk Inc. in the United States and other countries. All other brand names, product names, or trademarks belong to their respective owners. © 2021 Splunk Inc. All rights reserved.

Splunk Inc.
Condensed Consolidated Statements of Operations
(In thousands, except per share amounts)
(Unaudited)
 
 

Three Months Ended January 31,

Fiscal Year Ended January 31,

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 
Revenues
License

$

405,954

 

$

517,542

 

$

971,378

 

$

1,373,367

 

Cloud services

 

171,396

 

 

99,413

 

 

554,132

 

 

312,358

 

Maintenance and services

 

167,728

 

 

174,227

 

 

703,875

 

 

673,201

 

Total revenues

 

745,078

 

 

791,182

 

 

2,229,385

 

 

2,358,926

 

Cost of revenues
License

 

4,315

 

 

6,702

 

 

20,864

 

 

24,116

 

Cloud services

 

75,718

 

 

52,985

 

 

252,290

 

 

161,510

 

Maintenance and services

 

69,863

 

 

68,151

 

 

274,191

 

 

244,162

 

Total cost of revenues

 

149,896

 

 

127,838

 

 

547,345

 

 

429,788

 

Gross profit

 

595,182

 

 

663,344

 

 

1,682,040

 

 

1,929,138

 

Operating expenses
Research and development

 

211,383

 

 

197,513

 

 

791,026

 

 

619,800

 

Sales and marketing

 

369,999

 

 

367,116

 

 

1,336,056

 

 

1,263,873

 

General and administrative

 

100,398

 

 

106,484

 

 

335,144

 

 

332,602

 

Total operating expenses

 

681,780

 

 

671,113

 

 

2,462,226

 

 

2,216,275

 

Operating loss

 

(86,598

)

 

(7,769

)

 

(780,186

)

 

(287,137

)

Interest and other income (expense), net
Interest income

 

1,412

 

 

8,769

 

 

13,850

 

 

54,142

 

Interest expense

 

(34,519

)

 

(24,722

)

 

(123,076

)

 

(96,249

)

Other income (expense), net

 

(16,169

)

 

(999

)

 

(11,636

)

 

(2,407

)

Total interest and other income (expense), net

 

(49,276

)

 

(16,952

)

 

(120,862

)

 

(44,514

)

Loss before income taxes

 

(135,874

)

 

(24,721

)

 

(901,048

)

 

(331,651

)

Income tax provision (benefit)

 

3,674

 

 

(1,993

)

 

6,932

 

 

5,017

 

Net loss

$

(139,548

)

$

(22,728

)

$

(907,980

)

$

(336,668

)

 
Basic and diluted net loss per share

$

(0.86

)

$

(0.15

)

$

(5.68

)

$

(2.22

)

 
Weighted-average shares used in computing basic and diluted net loss per share

 

162,009

 

 

155,915

 

 

159,744

 

 

151,949

 

Splunk Inc.
Condensed Consolidated Balance Sheets
(In thousands)
(Unaudited)
 
 
January 31, 2021 January 31, 2020
 
Assets
Current assets
Cash and cash equivalents

$

1,771,064

 

$

778,653

 

Investments, current

 

87,847

 

 

976,508

 

Accounts receivable, net

 

1,114,199

 

 

838,743

 

Prepaid expenses and other current assets

 

162,939

 

 

129,839

 

Deferred commissions, current

 

136,331

 

 

99,072

 

Total current assets

 

3,272,380

 

 

2,822,815

 

Investments, non-current

 

13,728

 

 

35,370

 

Accounts receivable, non-current

 

347,202

 

 

468,934

 

Operating lease right-of-use assets

 

356,296

 

 

267,086

 

Property and equipment, net

 

182,780

 

 

156,928

 

Intangible assets, net

 

206,153

 

 

238,415

 

Goodwill

 

1,334,888

 

 

1,292,840

 

Deferred commissions, non-current

 

69,637

 

 

88,990

 

Other assets

 

85,422

 

 

68,093

 

Total assets

$

5,868,486

 

$

5,439,471

 

Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable

$

9,319

 

$

18,938

 

Accrued compensation

 

281,986

 

 

286,159

 

Accrued expenses and other liabilities

 

202,959

 

 

177,822

 

Deferred revenue, current

 

1,030,484

 

 

829,377

 

Total current liabilities

 

1,524,748

 

 

1,312,296

 

Convertible senior notes, net

 

2,302,635

 

 

1,714,630

 

Operating lease liabilities

 

330,970

 

 

235,631

 

Deferred revenue, non-current

 

110,418

 

 

176,832

 

Other liabilities, non-current

 

5,710

 

 

653

 

Total non-current liabilities

 

2,749,733

 

 

2,127,746

 

Total liabilities

 

4,274,481

 

 

3,440,042

 

Stockholders’ equity
Common stock

 

163

 

 

157

 

Accumulated other comprehensive loss

 

(592

)

 

(5,312

)

Additional paid-in capital

 

4,063,885

 

 

3,566,055

 

Accumulated deficit

 

(2,469,451

)

 

(1,561,471

)

Total stockholders’ equity

 

1,594,005

 

 

1,999,429

 

Total liabilities and stockholders’ equity

$

5,868,486

 

$

5,439,471

 

Splunk Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
 
 
Three Months Ended January 31, Fiscal Year Ended January 31,

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 
Cash flows from operating activities
Net loss

$

(139,548

)

$

(22,728

)

$

(907,980

)

$

(336,668

)

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

 

26,397

 

 

21,582

 

 

93,666

 

 

67,661

 

Amortization of deferred commissions

 

42,878

 

 

29,275

 

 

142,095

 

 

104,353

 

Amortization of investment premiums (accretion of discounts), net

 

223

 

 

(1,584

)

 

(667

)

 

(9,553

)

Loss on strategic investment

 

4,500

 

 

 

 

4,500

 

 

 

Amortization of debt discount and issuance costs

 

27,322

 

 

20,679

 

 

98,977

 

 

80,156

 

Gain on extinguishment of convertible senior notes

 

 

 

 

 

(6,952

)

 

 

Repurchase of convertible senior notes attributable to the accreted interest related to debt discount

 

 

 

 

 

(22,149

)

 

 

Non-cash operating lease costs

 

9,627

 

 

(6,313

)

 

25,410

 

 

1,198

 

Stock-based compensation

 

166,174

 

 

166,496

 

 

618,655

 

 

545,424

 

Disposal of property and equipment

 

64

 

 

1,974

 

 

1,045

 

 

1,974

 

Deferred income taxes

 

(1,581

)

 

(5,722

)

 

(3,590

)

 

(6,120

)

Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable, net

 

(344,617

)

 

(365,503

)

 

(153,724

)

 

(679,891

)

Prepaid expenses and other assets

 

(31,020

)

 

(37,027

)

 

(45,476

)

 

(69,575

)

Deferred commissions

 

(60,230

)

 

(64,965

)

 

(160,001

)

 

(149,426

)

Accounts payable

 

(3,903

)

 

(4,312

)

 

(9,082

)

 

(5,441

)

Accrued compensation

 

(4,115

)

 

71,719

 

 

(3,805

)

 

58,898

 

Accrued expenses and other liabilities

 

17,311

 

 

(13,011

)

 

3,814

 

 

(10,392

)

Deferred revenue

 

266,752

 

 

150,609

 

 

134,402

 

 

119,766

 

Net cash used in operating activities

 

(23,766

)

 

(58,831

)

 

(190,862

)

 

(287,636

)

Cash flows from investing activities
Purchases of investments

 

 

 

(270,632

)

 

(87,135

)

 

(1,086,317

)

Maturities of investments

 

252,558

 

 

274,841

 

 

995,878

 

 

1,080,812

 

Acquisitions, net of cash acquired

 

(44,625

)

 

(18,574

)

 

(56,383

)

 

(594,870

)

Purchases of property and equipment

 

(8,800

)

 

(47,595

)

 

(37,107

)

 

(101,119

)

Capitalized software development costs

 

(3,899

)

 

(2,589

)

 

(14,602

)

 

(2,589

)

Other investment activities

 

 

 

(148

)

 

(3,461

)

 

(3,898

)

Net cash provided by (used in) investing activities

 

195,234

 

 

(64,697

)

 

797,190

 

 

(707,981

)

Cash flows from financing activities
Proceeds from the exercise of stock options

 

389

 

 

2,919

 

 

3,473

 

 

3,543

 

Proceeds from employee stock purchase plan

 

35,735

 

 

25,901

 

 

79,949

 

 

60,383

 

Proceeds from the issuance of convertible senior notes, net of issuance costs

 

 

 

 

 

1,246,544

 

 

 

Purchase of capped calls

 

 

 

 

 

(137,379

)

 

 

Partial repurchase of convertible senior notes

 

 

 

 

 

(668,929

)

 

 

Taxes paid related to net share settlement of equity awards

 

(91,541

)

 

 

 

(140,776

)

 

(164,160

)

Net cash provided by (used in) financing activities

 

(55,417

)

 

28,820

 

 

382,882

 

 

(100,234

)

Effect of exchange rate changes on cash and cash equivalents

 

2,750

 

 

(109

)

 

3,201

 

 

(1,661

)

Net increase (decrease) in cash and cash equivalents

 

118,801

 

 

(94,817

)

 

992,411

 

 

(1,097,512

)

Cash and cash equivalents at beginning of period

 

1,652,263

 

 

873,470

 

 

778,653

 

 

1,876,165

 

Cash and cash equivalents at end of period

$

1,771,064

 

$

778,653

 

$

1,771,064

 

$

778,653

 

Splunk Inc.

Operating Metrics

Total Annual Recurring Revenue (“Total ARR”) represents the annualized revenue run-rate of active subscription, term license, and maintenance contracts at the end of a reporting period. Cloud Annual Recurring Revenue (“Cloud ARR”) represents the annualized revenue run-rate of active subscription contracts at the end of a reporting period. Contracts are annualized by dividing the total contract value by the number of days in the contract term and then multiplying by 365.

Non-GAAP Financial Measures and Reconciliations

To supplement Splunk’s condensed consolidated financial statements, which are prepared and presented in accordance with generally accepted accounting principles in the United States (“GAAP”), Splunk provides investors with the following non-GAAP financial measures: cloud services cost of revenues, cloud services gross margin, cost of revenues, gross margin, research and development expense, sales and marketing expense, general and administrative expense, operating income (loss), operating margin, income tax provision (benefit), net income (loss), net income (loss) per share and free cash flow (collectively the “non-GAAP financial measures”). These non-GAAP financial measures exclude all or a combination of the following (as reflected in the following reconciliation tables): expenses related to stock-based compensation and related employer payroll tax, amortization of intangible assets, restructuring and facility exit charges, acquisition-related adjustments, capitalized software development costs, a legal settlement charge, non-cash interest expense related to convertible senior notes, a gain on extinguishment of convertible senior notes and a strategic investment impairment. The non-GAAP financial measures are also adjusted for Splunk’s estimated tax rate on non-GAAP income (loss). To determine the estimated non-GAAP tax rate, Splunk evaluates financial projections based on its non-GAAP results and the tax effect of those projections. The estimated non-GAAP tax rate takes into account many factors including our operating structure and tax positions. The non-GAAP tax rate applied to the three and twelve months ended January 31, 2021 was 20%. The applicable fiscal 2020 tax rates are noted in the reconciliations. In addition, non-GAAP financial measures include free cash flow, which represents operating cash flow less purchases of property and equipment. Splunk considers free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated or used by the business.

Splunk excludes stock-based compensation expense because it is non-cash in nature and excluding this expense provides meaningful supplemental information regarding Splunk’s operational performance and allows investors the ability to make more meaningful comparisons between Splunk’s operating results and those of other companies. Splunk excludes employer payroll tax expense related to employee stock plans in order for investors to see the full effect that excluding that stock-based compensation expense had on Splunk’s operating results. These expenses are tied to the exercise or vesting of underlying equity awards and the price of Splunk’s common stock at the time of vesting or exercise, which may vary from period to period independent of the operating performance of Splunk’s business. Splunk also excludes amortization of intangible assets, restructuring and facility exit charges, acquisition-related adjustments, capitalized software development costs, a legal settlement charge, non-cash interest expense related to convertible senior notes, a gain on extinguishment of convertible senior notes and a strategic investment impairment from the applicable non-GAAP financial measures because these adjustments are considered by management to be outside of Splunk’s core operating results.

There are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by Splunk’s competitors and exclude expenses that may have a material impact upon Splunk’s reported financial results. Further, stock-based compensation expense has been and will continue to be, for the foreseeable future, a significant recurring expense in Splunk’s business and an important part of the compensation provided to Splunk’s employees. The presentation of the non-GAAP financial measures is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. Splunk uses these non-GAAP financial measures for financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons. Splunk believes that these non-GAAP financial measures provide useful information about Splunk’s operating results, enhance the overall understanding of past financial performance and future prospects and allow for greater transparency with respect to key metrics used by management in its financial and operational decision making. In addition, these non-GAAP financial measures facilitate comparisons to competitors’ operating results. The non-GAAP financial measures are meant to supplement and be viewed in conjunction with GAAP financial measures.

The following tables reconcile Splunk’s GAAP results to Splunk’s non-GAAP results included in this press release.

SPLUNK INC.
Reconciliation of GAAP to Non-GAAP Financial Measures
(In thousands, except per share data)
(Unaudited)
 
 
 
Reconciliation of Cash Used in Operating Activities to Free Cash Flow
 

Three Months Ended January 31,

Fiscal Year Ended January 31,

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Net cash used in operating activities

$

(23,766

)

$

(58,831

)

$

(190,862

)

$

(287,636

)

Less purchases of property and equipment

 

(8,800

)

 

(47,595

)

$

(37,107

)

 

(101,119

)

Free cash flow (non-GAAP)

$

(32,566

)

$

(106,426

)

$

(227,969

)

$

(388,755

)

Net cash provided by (used in) investing activities

$

195,234

 

$

(64,697

)

$

797,190

 

$

(707,981

)

Net cash provided by (used in) financing activities

$

(55,417

)

$

28,820

 

$

382,882

 

$

(100,234

)

Reconciliation of GAAP to Non-GAAP Financial Measures
Three Months Ended January 31, 2021
GAAP Stock-based
compensation
and related
employer payroll
tax
Amortization
of intangible
assets
Acquisition-
related
adjustments
Restructuring
and facility
exit charges
Capitalized
software
development
costs
Non-cash
interest expense
related to
convertible
senior notes
Impairment of
strategic
investment
Income tax
adjustment (2)
Non-GAAP
Cloud services cost of revenues

$

75,718

 

$

(3,105

)

$

(7,163

)

$

 

$

257

 

$

 

$

 

$

 

$

 

$

65,707

 

Cloud services gross margin

 

55.8

%

 

1.8

%

 

4.2

%

 

%

 

(0.1

)%

 

%

 

%

 

%

 

%

 

61.7

%

Cost of revenues

 

149,896

 

 

(15,947

)

 

(9,862

)

 

 

 

257

 

 

(594

)

 

 

 

 

 

 

 

123,750

 

Gross margin

 

79.9

%

 

2.1

%

 

1.3

%

 

%

 

%

 

0.1

%

 

%

 

%

 

%

 

83.4

%

Research and development

 

211,383

 

 

(74,640

)

 

 

 

 

 

(2,972

)

 

3,899

 

 

 

 

 

 

 

 

137,670

 

Sales and marketing

 

369,999

 

 

(48,789

)

 

(4,746

)

 

 

 

 

 

 

 

 

 

 

 

 

 

316,464

 

General and administrative

 

100,398

 

 

(30,669

)

 

 

 

(1,119

)

 

 

 

 

 

 

 

 

 

 

 

68,610

 

Operating income (loss)

 

(86,598

)

 

170,045

 

 

14,608

 

 

1,119

 

 

2,715

 

 

(3,305

)

 

 

 

 

 

 

 

98,584

 

Operating margin

 

(11.6

)%

 

22.7

%

 

1.9

%

 

0.2

%

 

0.4

%

 

(0.4

)%

 

%

 

%

 

%

 

13.2

%

Income tax provision

 

3,674

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

12,552

 

 

16,226

 

Net income (loss)

$

(139,548

)

$

170,045

 

$

14,608

 

$

1,119

 

$

2,715

 

$

(3,305

)

$

27,322

 

$

4,500

 

$

(12,552

)

$

64,904

 

Net income (loss) per share (1)

$

(0.86

)

$

0.38

 

___________________________

(1)

 

GAAP net loss per share calculated based on 162,009 weighted-average shares of common stock. Non-GAAP net income per share calculated based on 168,711 diluted weighted-average shares of common stock, which includes 6,702 potentially dilutive shares related to employee stock awards and conversion spread on our convertible notes. GAAP to non-GAAP net income (loss) per share is not reconciled due to the difference in the number of shares used to calculate basic and diluted weighted-average shares of common stock.

(2)

 

Represents the income tax adjustment using our estimated non-GAAP tax rate of 20%.

Reconciliation of GAAP to Non-GAAP Financial Measures
Three Months Ended January 31, 2020
GAAP Stock-based
compensation
and related
employer payroll tax
Amortization
of intangible
assets
Restructuring
and facility
exit charges
Capitalized
software
development
costs
Legal
settlement
charge
Non-cash interest
expense related to
convertible senior
notes
Income tax
adjustment (2)
Non-GAAP
Cloud services cost of revenues

$

52,985

 

$

(2,756

)

$

(4,488

)

$

 

$

 

$

 

$

 

$

 

$

45,741

 

Cloud services gross margin

 

46.7

%

 

2.8

%

 

4.5

%

 

%

 

%

 

%

 

%

 

%

 

54.0

%

Cost of revenues

 

127,838

 

 

(13,136

)

 

(9,854

)

 

 

 

 

 

 

 

 

 

 

 

104,848

 

Gross margin

 

83.8

%

 

1.7

%

 

1.2

%

 

%

 

%

 

%

 

%

 

%

 

86.7

%

Research and development

 

197,513

 

 

(59,865

)

 

(25

)

 

(5,628

)

 

2,589

 

 

 

 

 

 

 

 

134,584

 

Sales and marketing

 

367,116

 

 

(68,156

)

 

(4,333

)

 

 

 

 

 

 

 

 

 

 

 

294,627

 

General and administrative

 

106,484

 

 

(29,733

)

 

 

 

(482

)

 

 

 

(10,000

)

 

 

 

 

 

66,269

 

Operating income (loss)

 

(7,769

)

 

170,890

 

 

14,212

 

 

6,110

 

 

(2,589

)

 

10,000

 

 

 

 

 

 

190,854

 

Operating margin

 

(1.0

)%

 

21.5

%

 

1.8

%

 

0.8

%

 

(0.3

)%

 

1.3

%

 

%

 

%

 

24.1

%

Income tax provision (benefit)

 

(1,993

)

 

 

 

 

 

 

 

 

 

 

 

 

 

40,910

 

 

38,917

 

Net income (loss)

$

(22,728

)

$

170,890

 

$

14,212

 

$

6,110

 

$

(2,589

)

$

10,000

 

$

20,679

 

$

(40,910

)

$

155,664

 

Net income (loss) per share (1)

$

(0.15

)

$

0.96

 

___________________________

(1)

 

GAAP net loss per share calculated based on 155,915 weighted-average shares of common stock. Non-GAAP net income per share calculated based on 161,389 diluted weighted-average shares of common stock, which includes 5,474 potentially dilutive shares related to employee stock awards. GAAP to non-GAAP net income (loss) per share is not reconciled due to the difference in the number of shares used to calculate basic and diluted weighted-average shares of common stock.

(2)

 

Represents the income tax adjustment using our estimated non-GAAP tax rate of 20%.

Reconciliation of GAAP to Non-GAAP Financial Measures
Fiscal Year Ended January 31, 2021
GAAP Stock-based
compensation
and related
employer payroll
tax
Amortization
of intangible

assets
Acquisition
-related
adjustments
Restructuring
and facility
exit charges
Capitalized
software
development
costs
Non-cash
interest expense
related to
convertible
senior notes
Impairment
of strategic
investment
Income tax
adjustment (4)
Non-GAAP
Cloud services cost of revenues

$

252,290

 

$

(11,026

)

$

(23,169

)

$

 

$

28

 

$

 

$

 

$

 

$

 

$

218,123

 

Cloud services gross margin

 

54.5

%

 

2.0

%

 

4.1

%

 

%

 

%

 

%

 

%

 

%

 

%

 

60.6

%

Cost of revenues

 

547,345

 

 

(58,828

)

 

(40,245

)

 

 

 

(240

)

 

(1,188

)

 

 

 

 

 

 

 

446,844

 

Gross margin

 

75.4

%

 

2.6

%

 

1.9

%

 

%

 

%

 

0.1

%

 

%

 

%

 

%

 

80.0

%

Research and development

 

791,026

 

 

(278,677

)

 

(25

)

 

 

 

(5,856

)

 

14,602

 

 

 

 

 

 

 

 

521,070

 

Sales and marketing

 

1,336,056

 

 

(206,380

)

 

(17,745

)

 

 

 

(1,168

)

 

 

 

 

 

 

 

 

 

1,110,763

 

General and administrative

 

335,144

 

 

(95,545

)

 

 

 

(3,342

)

 

(518

)

 

 

 

 

 

 

 

 

 

235,739

 

Operating loss

 

(780,186

)

 

639,430

 

 

58,015

 

 

3,342

 

 

7,782

 

 

(13,414

)

 

 

 

 

 

 

 

(85,031

)

Operating margin

 

(35.0

)%

 

28.7

%

 

2.7

%

 

0.1

%

 

0.3

%

 

(0.6

)%

 

%

 

%

 

%

 

(3.8

)%

Income tax provision (benefit)

 

6,932

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(28,711

)

 

(21,779

)

Net loss

$

(907,980

)

$

639,430

 

$

58,015

 

$

3,342

 

$

8,258

 

(2

)

$

(13,414

)

$

92,024

 

(3

)

$

4,500

 

$

28,711

 

$

(87,114

)

Net loss per share (1)

$

(5.68

)

$

4.00

 

$

0.35

 

$

0.02

 

$

0.05

 

$

(0.08

)

$

0.58

 

$

0.03

 

$

0.18

 

$

(0.55

)

___________________________

(1)

 

Calculated based on 159,744 weighted-average shares of common stock.

(2)

 

Includes a $0.5 million loss on disposal of property, plant and equipment.

(3)

 

Includes non-cash interest expense of $99.0 million and a $7.0 million non-recurring gain on extinguishment of convertible senior notes.

(4)

 

Represents the income tax adjustment using our estimated non-GAAP tax rate of 20%.

Reconciliation of GAAP to Non-GAAP Financial Measures
Fiscal Year Ended January 31, 2020
GAAP Stock-based
compensation
and related
employer payroll
tax
Amortization
of intangible
assets
Acquisition
-related
adjustments
Restructuring
and facility
exit charges
Capitalized
software
development
costs
Legal
settlement
charge
Non-cash
interest expense
related to
convertible
senior notes
Income tax
adjustment (2)
Non-GAAP
Cloud services cost of revenues

$

161,510

 

$

(7,465

)

$

(7,822

)

$

 

$

 

$

 

$

 

$

 

$

 

$

146,223

 

Cloud services gross margin

 

48.3

%

 

2.4

%

 

2.5

%

 

%

 

%

 

%

 

%

 

%

 

%

 

53.2

%

Cost of revenues

 

429,788

 

 

(46,478

)

 

(29,516

)

 

 

 

 

 

 

 

 

 

 

 

 

 

353,794

 

Gross margin

 

81.8

%

 

1.9

%

 

1.3

%

 

%

 

%

 

%

 

%

 

%

 

%

 

85.0

%

Research and development

 

619,800

 

 

(190,404

)

 

(697

)

 

(12

)

 

(5,628

)

 

2,589

 

 

 

 

 

 

 

 

425,648

 

Sales and marketing

 

1,263,873

 

 

(223,812

)

 

(8,324

)

 

(172

)

 

 

 

 

 

 

 

 

 

 

 

1,031,565

 

General and administrative

 

332,602

 

 

(101,939

)

 

 

 

(7,408

)

 

(482

)

 

 

 

(10,000

)

 

 

 

 

 

212,773

 

Operating income (loss)

 

(287,137

)

 

562,633

 

 

38,537

 

 

7,592

 

 

6,110

 

 

(2,589

)

 

10,000

 

 

 

 

 

 

335,146

 

Operating margin

 

(12.2

)%

 

23.9

%

 

1.6

%

 

0.3

%

 

0.3

%

 

(0.1

)%

 

0.4

%

 

%

 

%

 

14.2

%

Income tax provision

 

5,017

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

69,141

 

 

74,158

 

Net income (loss)

$

(336,668

)

$

562,633

 

$

38,537

 

$

7,592

 

$

6,110

 

$

(2,589

)

$

10,000

 

$

80,157

 

$

(69,141

)

$

296,631

 

Net income (loss) per share (1)

$

(2.22

)

$

1.88

 

___________________________

(1)

 

GAAP net loss per share calculated based on 151,949 weighted-average shares of common stock. Non-GAAP net income per share calculated based on 157,815 diluted weighted-average shares of common stock, which includes 5,866 potentially dilutive shares related to employee stock awards. GAAP to non-GAAP net income (loss) per share is not reconciled due to the difference in the number of shares used to calculate basic and diluted weighted-average shares of common stock.

(2)

 

Represents the income tax adjustment using our estimated non-GAAP tax rate of 20%.

 

Media Contact

Bill Bode

Splunk Inc.

[email protected]

Investor Contact

Ken Tinsley

Splunk Inc.

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Networks Internet Data Management Technology Software

MEDIA:

RADA Announces Proposed Public Offering of Ordinary Shares

NETANYA, Israel, March 03, 2021 (GLOBE NEWSWIRE) — RADA Electronic Industries Ltd. (“RADA”) (NASDAQ and TASE: RADA), a global defense technology company, today announced that it intends to offer and sell its ordinary shares in an underwritten public offering. RADA also expects to grant to the underwriters a 30-day option to purchase up to an additional 15% of its ordinary shares sold in the offering on the same terms and conditions.  There can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the offering.

RADA intends to use the net proceeds from this offering for general corporate purposes.

Jefferies LLC, Baird and Canaccord Genuity are acting as joint bookrunners for this offering. A.G.P./Alliance Global Partners is acting as lead manager in the offering.

The offering is being made pursuant to an effective shelf registration statement (File No. 333-252015) declared effective by the Securities and Exchange Commission on January 21, 2021. A prospectus supplement and accompanying base prospectus relating to the offering will be filed with the Securities and Exchange Commission. When available, copies of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained from the Securities and Exchange Commission at http://www.sec.gov, Alternatively, copies of the prospectus supplement and accompanying base prospectus may be obtained from Jefferies LLC Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at [email protected]; Robert W. Baird & Co. Incorporated, Attention: Syndicate Department, 777 East Wisconsin Avenue, Milwaukee, WI 53202, by telephone at (800) 792-2473 or by email at [email protected]; and Canaccord Genuity LLC, Attention: Syndicate Department, 99 High Street, Suite 1200, Boston, MA 02110, by email at [email protected].

This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities law of any such state or jurisdiction.

About RADA

RADA is a global defense technology company focused on proprietary radar solutions and legacy avionics systems. The Company is a leader in mini-tactical radars, serving attractive, high-growth markets, including critical infrastructure protection, border surveillance, active military protection and counter-drone applications.

Safe Harbor Statement

Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995, including statements regarding RADA’s expectations with respect to its proposed offering and its intended use of proceeds from the offering. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties associated with market conditions, as well as risks and uncertainties inherent in RADA’s business, including, but not limited to, changes in general economic conditions, risks in product and technology developments, market acceptance of new products and continuing product demand, level of competition and other factors described in RADA’s Annual Report on Form 20-F for the year ended December 31, 2020, and other filings with the Securities and Exchange Commission.

Company Contact:
Avi Israel, CFO
Tel: +972-765-386-200        
[email protected]
www.rada.com
Investor Relations Contact:
GK Investor Relations
Ehud Helft
Tel: 1 646 688 3559
[email protected]



Ampio Pharmaceuticals, Inc. Reports Fourth Quarter 2020 Financial Results and Provides Business Update

FDA recommends we conduct a randomized, double-blinded, placebo-controlled Phase II for Intravenous (IV) and Inhaled Ampion to allow consideration of EUA treatment of COVID-19 patients

PR Newswire

ENGLEWOOD, Colo., March 3, 2021 /PRNewswire/ — Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today reported annual financial results for the year ended December 31, 2020 and provided a corporate overview / business update.

Mr. Michael Macaluso, President and CEO, noted, “The FDA has recently responded to our requests to expand our IV and Inhalation Covid-19 studies, utilizing Ampion, by recommending we conduct a randomized, double-blinded, placebo-controlled Phase II trial in each.  They also indicated that their recommended trial design for both will allow for an effective and efficient review of data results, determine the safety and statistical significance and effectiveness of Ampion in comparison to Standard of Care, all of which are necessary for the FDA to objectively determine that the known and potential benefits of Ampion outweigh the known and potential risks and, consequently, Ampion may be considered for emergency use authorization (EUA).

In addition, we have provided a detailed proposal to the FDA in response to their recent guidance regarding the status of our Osteoarthritis of the Knee (OAK) Phase III clinical trial, which is paused as a result of the COVID pandemic.  In summary, our response proposes analysis of the existing data in a reduced level of patients who had completed the 12-week study regimen for submission.  It is important to note that this response is part of  an ongoing active dialog with the FDA and until the FDA renders a final decision, this trial data will continue to remain paused and blinded to ensure clinical trial integrity.

Ampion is a platform biologic and, as such, is agnostic to whether it is treating a COVID patient or an osteoarthritis auto- immune condition. Simplified, Ampion directly and effectively addresses inflammation.  Consequently, our ongoing and continued research and clinical trials may be applicable to a significant number of additional disease complications, not just COVID.”

Mr. Michael Macaluso, President and Chief Executive Officer, Dr. David Bar-Or, Director and Founder, Ms. Holli Cherevka, Chief Operating Officer and Mr. Daniel Stokely, Chief Financial Officer will be hosting a Conference Call for the Investment Community this afternoon beginning at 4:30 PM ET (see details below). 

The key areas of focus will be as follows:


COVID-19 Platform / Pipeline Overview and Update

  • AP-014 (inhaled) and AP-016 (intravenous) clinical trial update
  • Possibility of obtaining an Emergency Use Authorization (EUA) from the FDA for inhaled and intravenous Ampion


OAK Clinical Trial 2021 Timeline / Update

  • Ampio’s Osteoarthritis of the Knee (OAK) Phase III trial being conducted under a Special Protocol Assessment (SPA) with the FDA
  • Ampio harmonizes steps for OAK Phase III trial with the FDA guidance during the COVID-19 health emergency and submitted an SPA amendment to the FDA


PASC/Long Hauler and Other Clinical Trial 2021 Timelines / Updates

  • Status of PASC/Long Hauler Study
  • Kidney Disease
  • Pediatric diseases

Financial Results for Year Ended December 31, 2020

Cash and cash equivalents totaled $17.3 million at December 31, 2020, compared to $6.5 million at December 31, 2019. The increase is attributable to net proceeds received from the utilization of our at-the-market (ATM) equity offering and warrant exercises totaling $25.6 million, partially offset by cash used to fund operating activities of $14.7 million.

Research and development expenditures for the year ended December 31, 2020 were $9.2 million, compared to $12.6 million for the same period in 2019. The decrease in research and development expenses for the year ended December 31, 2020 compared to the amounts for the same period in 2019 was primarily due to the AP-013 study being temporarily paused in April 2020 as a result of the stay-at-home mandates issued by state and federal governments in response to the COVID-19 pandemic and travel restrictions implemented by the Company’s contracted Clinical Research Organization (CRO), partially offset by expenses associated with the inhaled Ampion safety study, the AP-014 (inhaled Ampion) Phase I study and the AP-016 (intravenous Ampion) Phase I study, which were all initiated during the 2020 period.

General and administrative expenses for the year ended December 31, 2020 were $6.7 million, compared to $6.0 million for the same period in 2019. The increase in general and administrative expenses for the year ended December 31, 2020 compared with the same period for 2019 is primarily due to the increase in directors and officer’s insurance premiums, which was consistent with the overall market for coverage, and an increase in stock-based compensation expense as a result of the issuance and repricing of stock options. 

Other expense was negligible for the year ended December 31, 2020 compared to other income of $5.0 million for the same period in 2019. In fiscal 2019, a derivative gain was recorded from previously issued investor warrants as a result of (i) the current year exercise of investor warrants and (ii) the overall increase in the price of the Company’s stock at December 31, 2020. This was partially offset by the income recognized in the current year from the Payroll Protection Funding Program, whereby the Company believes it is probable that the loan will be forgiven by the Small Business Administration as the loan has already been forgiven by the Company’s lending institution.

Net loss for the year ended December 31, 2020 was $15.9 million, or $0.09 on a fully diluted per share basis, compared to a net loss of $13.6 million, or $0.14 on a fully diluted per share basis, for the same period in 2019. The higher net loss reported for the year ended December 31, 2020 compared to the same period for 2019 is primarily attributable to a reduction in other income as a result of the recognition of a derivative loss on previously issued investor warrants, partially offset by a reduction in clinical trial and related costs as a result of pausing the AP-013 study in early 2020 due to the COVID-19 pandemic. 

The total shares of common stock outstanding were 193,378,996 at December 31, 2020, compared to 158,644,757 at December 31, 2019.

Financial Guidance

Based on its current operating plans and expected access to equity financing, Ampio expects to have cash and access to external sources of liquidity sufficient to fund research and development programs and operations through the first quarter of 2022.

Conference Call and Webcast

Ampio will host a conference call today at 4:30pm EST (1:30 pm PST) to discuss these 2020 annual results and provide a corporate business update. 

The live call / webcast may be accessed as follows:

Domestic:

888-506-0062 
Conference ID # 441054

International:

973-528-0011 
Conference ID # 441054

Webcast Link:



https://www.webcaster4.com/Webcast/Page/2569/39961

The conference call will also be available from the Investors Relations section of the Company’s website at www.ampiopharma.com and will be archived there shortly after the live event.

Receipt of Audit Opinion with Going Concern Qualification

Pursuant to the disclosure requirements of the NYSE American Company Guidelines Sections 401(h) and 610(b), Ampio is reporting that its audited financial statements for the fiscal year ended December 31, 2020, included in Ampio’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 3, 2021, contains an audit opinion from its independent registered public accounting firm that includes an explanatory paragraph related to Ampio’s ability to continue as a going concern. This announcement does not represent any change or amendment to the Company’s financial statements or to its Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of Ampion, our product candidate, to treat prevalent inflammatory conditions for which there are limited treatment options. Ampio’s lead drug, Ampion, is backed by an extensive patent portfolio with intellectual property protection extending through 2035 and will be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the Biologics Price Competition and Innovation Act of 2009 (BPCIA).

Forward Looking Statements

Ampio’s statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “believe,” “expect,” “plan,” “anticipate,” and similar expressions. These forward-looking statements include statements regarding Ampio’s ability to fund research and development programs and operations into 2022, expectations with respect to Ampion, including its ability to treat prevalent inflammatory conditions for which there are limited treatment options,  the term of Ampio’s patent protection and the timing and likelihood of Ampion’s approval as a novel biologic under the BPCIA, including the availability of 12-year FDA market exclusivity in connection with such approval. These forward-looking statements are made on the basis of the current beliefs, expectations, and assumptions of the management of Ampio and are subject to significant risks and uncertainties that could cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. The risks and uncertainties involved include those detailed from time to time in Ampio’s filings with the Securities and Exchange Commission, including without limitation, in Ampio’s Annual Report on Form 10-K and other documents filed with the Securities and Exchange Commission. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.


Ampio Pharmaceuticals, Inc.


Balance Sheets


December 31, 


December 31, 


2020


2019


Assets

Current assets

Cash and cash equivalents

$

17,346,000

$

6,532,000

Prepaid expenses and other

1,147,000

1,718,000

Total current assets

18,493,000

8,250,000

Fixed assets, net

3,561,000

4,748,000

Right-of-use asset

824,000

1,003,000

Total assets

$

22,878,000

$

14,001,000


Liabilities and Stockholders’ Equity

Current liabilities

Accounts payable and accrued expenses

$

1,550,000

$

4,025,000

Lease liability-current portion

284,000

259,000

Total current liabilities

1,834,000

4,284,000

Lease liability-long-term

925,000

1,210,000

Warrant derivative liability

2,607,000

2,064,000

Total liabilities

5,366,000

7,558,000

Commitments and contingencies (Note 8)

Stockholders’ equity

Preferred Stock, par value $0.0001; 10,000,000 shares authorized; none issued

Common Stock, par value $0.0001; 300,000,000 shares authorized; shares issued and outstanding – 193,378,996 as of December 31, 2020 and 158,644,757 as of December 31, 2019

19,000

16,000

Additional paid-in capital

218,020,000

191,060,000

Accumulated deficit

(200,527,000)

(184,633,000)

Total stockholders’ equity

17,512,000

6,443,000

Total liabilities and stockholders’ equity

$

22,878,000

$

14,001,000

 


Ampio Pharmaceuticals, Inc.


Statements of Operations


Year Ended December 31, 


2020


2019

Operating expenses

Research and development

$

9,172,000

$

12,622,000

General and administrative

6,662,000

5,954,000

Total operating expenses

15,834,000

18,576,000

Other (expense) income

Interest income

12,000

77,000

Paycheck Protection Program funding

544,000

Derivative (loss) gain

(543,000)

4,869,000

Loss on disposal of fixed asset

(73,000)

Total other (expense) income

(60,000)

4,946,000

Net loss

$

(15,894,000)

$

(13,630,000)

Net loss per common share:

Basic

$

(0.09)

$

(0.10)

Diluted

$

(0.09)

$

(0.14)

Weighted average number of common shares outstanding:

Basic

172,846,773

130,601,500

Diluted

172,846,773

131,135,178

Company Contact
s

Investor Relations

Joe Hassett

[email protected]

484-686-6600

Media Contact

Katie Kennedy


[email protected]

610-731-1045

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ampio-pharmaceuticals-inc-reports-fourth-quarter-2020-financial-results-and-provides-business-update-301239968.html

SOURCE Ampio Pharmaceuticals, Inc.